Bayer's Polymers segment comprises five business groups: Plastics, Rubber, Polyurethanes, Coatings and Colorants, including the subsidiaries Bayer Faser GmbH (fibers).


The Plastics Business Group supplies a broad range of engineering thermoplastics and high-tech semifinished products to meet the differing requirements of a wide variety of industries.

Films Makrofol / Bayfol PC / PC-Blends
Polyamides and Polyesters Durethan A PA 66
  Durethan B + T PA 6
  Pocan PBT / PET
Polycarbonates Apec PC-HT
  Makrolon PC
Styrenics Bayblend PC+ABS
  Lustran ABS ABS
  Lustran SAN SAN
  Novodur ABS ABS
  Triax ABS+PA
Thermoplastic Polyurethanes Desmopan TPU


As a leading supplier of raw materials, Bayer is among the most important partners to the rubber and tire industry. The portfolio of the Rubber Business Group comprises synthetic rubber, rubber chemicals and modifiers for the plastics industry, along with special preparations and processing chemicals from Bayer subsidiary RheinChemie and latices from PolymerLatex, a joint venture with Degussa-Huls AG.

Tradename Chemical Description Abbreviation
Bayer Bromobutyl Bromobutyl rubber BIIR
Bayer Butyl Butyl rubber IIR
Bayer Chlorobutyl Chlorobutyl rubber CIIR
Baypren®  Chloroprene rubber CR
Buna®  BL Styrene-butadiene diblock copolymers SB
Buna®  CB Butadiene rubber for plastic modification BR
Buna®  EP Ethylene-propylene rubber EPM/EPDM
Buna®  SL Solution styrene-butadiene rubber S-SBR
Buna®  VSL Solution vinyl-butadiene-styrene-butadiene rubber S-VSBR
Krylene®  Emulsion styrene-butadiene rubber E-SBR
Krynac®  Acrylonitrile-butadiene rubber NBR
Krynol®  Emulsion styrene-butadiene rubber E-SBR
Levamelt Ethylene-vinyl acetate rubber EVM
Levapren®  Ethylene-vinyl acetate rubber EVM
Perbunan®  NT Acrylonitrile-butadiene rubber NBR
Polysar®  S Styrene-butadiene rubber SBR
Taktene®  Black masterbatches BR
Taktene®  Butadiene rubber for plastic modification BR
Taktene®  Butadiene rubber BR
Therban®  Hydrogenated acrylonitrile-butadiene rubber HNBR


The Polyurethanes Business Group (PU) is the world's leading supplier of polyurethane raw materials and systems. The development of new products and technologies, along with intensive customer support in all regions of the world, is an integral element of PU's strategy for success. Regional business service centers strengthen our ties to customers and accelerate business processes.
We offer our customers a comprehensive service package that includes expertise in the processing of polyurethane systems and in the design and functional performance of polyurethane products. The broad spectrum of applications for Bayer polyurethanes stretches from solid materials to foams with a wide range of properties.

Coatings and Colorants

This business group consolidates all products used as raw materials in coatings, sealants and adhesives and as colorants for plastics and construction materials.Environmental compatibility is at the forefront in the development of new products such as high-grade, high-solids and aqueous binders.


Established in 1994 in Dormagen, Germany, Bayer Faser GmbH is one of the leading fiber manufacturers in the world. Bayer fibers are used in all kinds of products - from clothing through carpets and home furnishings to fishing lines.

"The New Bayer"     

2002/7/1   社内体制として発足

2002/10/1  Bayer CropScience AG 独立 

2003/4/25   株主総会で分社承認 (上記CropScienceに加え)
Bayer HealthCare AG, Bayer Polymers AG and Bayer Chemicals AG.
Bayer Business Services GmbH, Bayer Technology Services GmbH
              and Bayer Industry Services GmbH & Co. OHG.


2003/4/28  Bayer USA 新組織発表
Bayer CropScience LP, Bayer Chemicals Corporation, Bayer HealthCare LLC,
           Bayer Polymers LLC and Bayer Pharmaceuticals Corporation.
           Bayer Corporate and Business Services LLC.


2003/10/2 バイエル ヘルスケア社、ケミカルズ社、テクノロジー サービス社が独立

2003/11  中核の化学事業分離 経営資源、医薬などに集中

2002/7/1 Bayer

New Bayer AG structure operational
Aiming for sustainable increase in corporate value / better placed for strategic options

Effective July 1, 2002, the Bayer Group is operating within its new organizational structure. In the future, the four operating subgroups and three service companies
under the umbrella of a management holding company ー will focus more strongly on their core competencies, making better use of growth opportunities and aiming for a sustainable improvement in performance. "In just seven months we have entirely realigned the Group and adapted it to both current and future market challenges," commented Bayer AG Management Board Chairman Werner Wenning. "In this way we have accomplished an important part of Bayer's restructuring."

For the moment the new structure only applies internally, with the future legal entities still being run as organizational units of Bayer AG. In October 2002
Bayer CropScience AG will also become legally independent with retroactive economic effect from January 1, 2002. The carve-out of the other companies is planned to take place in July 2003 with retroactive economic effect from January 1, 2003, after approval has been received from the 2003 Annual Stockholder's Meeting.

This biggest reorganization in Bayer's history is designed to enhance the Group's international competitiveness. According to Wenning: "With this reorganization we are separating strategic management from business operations to ensure that the future subgroups
Bayer Chemicals, Bayer CropScience, Bayer HealthCare and Bayer Polymers can act flexibly in their markets, make rapid, focused decisions and capitalize more quickly on innovations." They are also considerably better positioned for strategic options, including cooperations, joint ventures or strategic alliances, as well as acquisitions and divestments. "We expect the new structure to bring a sustainable increase in corporate value in the interests of shareholders, customers and employees alike," said Bayer's CEO.

In future the Bayer Group will be run by the Management Board of the new holding company which, apart from Wenning as Chairman, includes Klaus Kuhn (responsible for Finance), Dr. Udo Oels (Technology and Environment), Dr. Richard Pott (Strategy and Human Resources, labor director) and Werner Spinner (Business Excellence, Regions and Services). The holding company will deal with portfolio issues, strategy, budgets, finance and appointments to the principal managerial positions.

Chairman of the Board of Management of the future
Bayer HealthCare AG, which comprises the Pharmaceuticals, Consumer Care, Diagnostics, Biological Products and Animal Health business groups, is Dr. Frank Morich. The Management Board Chairman of Bayer CropScience AG, which combines Bayer's crop protection business with the recently acquired Aventis CropScience, is Dr. Jochen Wulff. Dr. Ulrich Koemm has been appointed Chairman of the Board of Management of Bayer Chemicals AG, which comprises the current Basic and Fine Chemicals and Specialty Products business groups along with subsidiaries H.C. Starck and Wolff Walsrode. Dr. Hagen Noerenberg becomes Chairman of the Board of Management for Bayer Polymers AG, which unites the activities of the current Plastics, Rubber, Polyurethanes, and Coatings and Colorants business groups.

* Service companies
   Bayer Business Services, Bayer Technology Services and Bayer Industry Services 

2003/4/25 株主総会

Consent is given to the Hive-Down and Transfer Agreements between the Company and Bayer HealthCare AG, Bayer Polymers AG and Bayer Chemicals AG.

Consent is given to the Hive-Down and Transfer Agreements between the Company and the service companies Bayer Business Services GmbH, Bayer Technology Services GmbH and Bayer Industry Services GmbH & Co. OHG..

(Bayer USA)
April 28,2003 Bayer USA

Bayer Launches New North American Organization and New Leadership

Bayer AG shareholders voted at their annual meeting to adopt a new organizational structure proposed by the Bayer AG Board of Management. The proposal represents for Bayer far-reaching changes that are expected to provide maximum operational and strategic flexibility and meet new challenges in the marketplace where the company competes. The company's Supervisory Board has approved the new global structure and executive appointments.

Consistent with the global reorganization, Bayer's U.S. subsidiary, Bayer Corporation, announced its new organizational structure and leadership team for North America. The new organization includes five operating companies and a service company within a management holding structure.

In 2002, Bayer had global sales of Euros 29.6 billion, of which approximately Euros 9 billion were from North American operations.

Bayer's new organization in the United States comprises five operating companies:
Bayer CropScience LP, Bayer Chemicals Corporation, Bayer HealthCare LLC, Bayer Polymers LLC and Bayer Pharmaceuticals Corporation. Separately, it has also created a service company, Bayer Corporate and Business Services LLC. These six businesses are under the umbrella of the holding company, Bayer Corporation.

As previously announced, Dr. Attila Molnar, the Senior Representative of Bayer in North America, is President and CEO of Bayer Corporation.

Bayer Polymers, Bayer Chemicals, Bayer Corporate and Business Services and the Bayer Corporation holding company are based in Pittsburgh.

Bayer's five operating companies -- CropScience, Chemicals, HealthCare, Polymers and Pharmaceuticals -- produce a broad range of products found in nearly every house, hospital, farm and factory across America. Its products help diagnose and treat diseases, purify water, preserve local landmarks, protect crops, advance automobile safety and durability and improve people's lives.

One of Fortune magazine's Most Admired Companies, Bayer promotes science literacy and hands-on education through its Making Science Make Sense educational initiative. Approximately 5 percent of Bayer's 21,600 employees volunteer in local schools, and more than 500 charitable organizations receive funding from the Bayer Foundation. In 2002, Bayer's diversity efforts were honored with the Catalyst Award for its Women: Leaders for the Global Marketplace program.

The worldwide Bayer Group is based in Leverkusen, Germany, and has some 120,000 employees. Its stock is a component of the DAX and is listed on the New York Stock Exchange (ticker symbol: BAY).

2002年10月03日 Chemnet Tokyo


October 1, 2002

Portfolio streamlining continues
Bayer divests Haarmann & Reimer

Bayer AG, Leverkusen, has sold its non-core Haarmann & Reimer subsidiary to the EQT Northern Europe Private Equity Funds. Closing of the deal today, October 1, 2002, means EQT acquires the business of the Holzminden, Germany-based fragrances and flavors manufacturer with immediate effect. Bayer will use the proceeds to reduce net debt.
The sale marks the completion of another stage in the streamlining of the Bayer Group's business portfolio. In recent months Bayer already divested company housing units, the interest in Agfa and the generics business in France and Spain. The further planned divestments of Rhein Chemie, PolymerLatex and the household insecticides business are expected to be accomplished in the near future.

October 4, 2002

Bayer plans to sell Rhein Chemie to Advent International         → 売却取り止め
Transfer scheduled for November 2002

Bayer AG intends to sell its subsidiary Rhein Chemie Rheinau GmbH, Mannheim, Germany, to a group of financial investors advised by Advent International Corporation, Boston, for EUR 215 million, including the assumption of debt. The transaction would include the wholly owned subsidiary iSL-Chemie GmbH & Co. KG of Kurten, Germany, as well as Rhein Chemie affiliates in the United States and Japan and a Chinese joint venture in which Rhein Chemie owns a 90 percent interest. It is planned to complete the sale at the beginning of November, subject to the approval of the relevant antitrust authorities.
"Under this new ownership, Rhein Chemie would have excellent prospects of further expanding its strong market position," commented Bayer AG Management Board Chairman Werner Wenning. In December 2001, Bayer announced its intention to divest Rhein Chemie and other subsidiaries so as to focus more closely on its core businesses. The sale of Holzminden, Germany-based subsidiary Haarmann & Reimer to the financial investor EQT was completed only a few days ago.

Founded in 1889, Rhein Chemie has been a subsidiary of Bayer AG since 1971. The company is an internationally successful supplier of specialties to the rubber, lubricant and plastic industries. Its 1,100 employees in Germany and around the world, including 550 in Mannheim, generated global sales in 2001 of approximately EUR 320 million. Rhein Chemie operates production facilities in Germany, the United States, China, Japan and other countries.

With more than 50 investments worldwide in the chemical and pharmaceutical industry, Advent International Corporation has extensive experience in this sector. Its investments in European companies include Vinnolit in Germany, Materis in France and Pemco in Belgium.

Advent International is one of the world's largest private equity firms with EUR 6 billion under management and offices in 14 countries. The company employs more than 100 experts in the United States, Europe, Latin America and Asia. Since its founding in 1984, Advent International has invested in over 500 companies. The chemical and pharmaceutical sector is one of Advent International's main fields of expertise in Europe.

December 5, 2002  Bayer 

Strategic options for Rhein Chemie under review

An agreement concluded in October 2002 between a U.S. financial investor and Bayer concerning the sale of Rhein Chemie has been dissolved by common consent of the parties, who were unable to agree on a number of outstanding points. Various strategic options are currently being considered.
Rhein Chemie is an internationally successful supplier of specialties to the rubber, lubricant and plastics industries. It also has a wholly owned subsidiary, iSL-Chemie GmbH & Co. KG in Kurten, Germany, affiliates in the United States and Japan, and owns a 90 percent interest in a joint venture in China.

March 26, 2003 Financial Times  

Bayer to keep Rhein Chemie.

After looking for a buyer for 15 months, Bayer AG of Leverkusen, Germany, has decided not to sell its Rhein Chemie Rheinau GmbH subsidiary. A $212 M deal with the US equity form
Advent International Corp fell through in Dec 2002. Rhein Chemie has been a Bayer subsidiary since 1971, employs 1100 people and had sales of $275 M in 2002. The company supplies products for the plastics industry, including release agents, vulcanisation agents and polymer-bound chemicals. The company also distributes Bayer's rubber polymer and rubber chemical products in the USA. It is likely to remain operating as an independent unit rather than joining the new Bayer Polymers AG structure.


日本経済新聞 2001/10/1

独バイエル 渦中の医薬継続  「総合化学」維持 道探る 「内向き」志向の改革カギ





他メーカー 得意分野に特化


October 28, 2002 Bayer

Bayer CropScience AG to sell a range of products to BASF
   Company on track with regulatory divestments subsequent to acquisition of Aventis CropScience

Bayer CropScience AG today announced that it intends to sell a package of selected insecticides and fungicides to BASF AG while retaining certain back-licenses for non-agricultural applications. The total package is valued at EUR 1,330 million. Taking into consideration the back-licenses the cash purchase price amounts to EUR 1,185 million. With the completion of the envisaged transaction, Bayer CropScience would fulfill within the given timeframe a major condition imposed by the European Commission and the U.S. Federal Trade Commission (FTC) as part of the Aventis CropScience acquisition. This transaction is subject to the approval by the European Commission and the U.S. Federal Trade Commission.
Following the respective consent orders the agreements with BASF contain assets and rights related to two insecticides (active ingredients: Fipronil, Ethiprole) and a number of fungicides (active ingredients: Prochloraz, Iprodione, Triticonazole, Fluquinconazole and Pyrimethanil) for certain regions and application fields. BASF will also acquire the Aventis CropScience manufacturing plant in Elbeuf, France. The total revenue from the products and operations involved in the transaction amounted to about EUR 500 million in 2001.

"After the sale of these products, Bayer CropScience can now focus entirely on developing its business and expanding its market position", said Werner Wenning, Chairman of the Board of Management of Bayer AG.

"Cash-in from the sale also contributes to improving the Group´s financials, as does the cash inflow from the other divestments we have already announced."

"Following a very competitive auction process and intensive negotiations with several interested parties we are pleased to have reached an agreement with BASF," added Dr. Jochen Wulff, Chairman of the Board of Management of Bayer CropScience AG. "The purchase price agreed represents a fair compensation for the required divestments. I am also pleased that we were able to retain licence rights to market Fipronil and its mixtures in certain non-agricultural markets within the scope of the FTC consent order," emphasized Wulff. "The integration of the Aventis CropScience operations is moving ahead quite rapidly and we continue to focus our efforts on the further integration and strategic development of the new Bayer CropScience."

Bayer CropScience AG, a subsidiary of Bayer AG with annual sales of some EUR 6.5 billion, is one of the world's leading innovative crop science companies in the areas of crop protection, seeds and green biotechnology, as well as non-agricultural pest control. The company offers an outstanding range of products and extensive service backup for modern, sustainable agriculture and for non-agricultural applications. Bayer CropScience has a global workforce of 22,000 and is represented in 122 countries, ensuring proximity to dealers and consumers.

Chemnet Tokyo 2003/03/06                   発表文



2003/3/4 Bayer

Bayer and Degussa sell PolymerLatex to Soros Private Equity Partners

Bayer AG of Leverkusen, Germany, and Degussa AG of Dusseldorf, Germany, are selling PolymerLatex GmbH & Co. KG, their Marl, Germany-based 50:50 joint venture, to the financial investment company Soros Private Equity Partners. The sales price amounts to approx. 235 million euros. The transaction is subject to the approval of the relevant antitrust authorities.
The sale of PolymerLatex completes the divestment program which Bayer launched at the end of 2001 as part of its Group-wide reorganization and strategic realignment project. The divestments included the subsidiary Haarmann & Reimer, the 30 percent interest in Agfa, a large proportion of the Bayer company apartments, the generics business in France and Spain and the household insecticide business. In addition, Bayer sold off numerous crop protection products and active ingredients which had to be divested or licensed out as a result of conditions imposed by the anti-trust authorities following the take-over of Aventis CropScience. Through the cash inflow from the divestment program Bayer has been able to cut its net debt, which had increased significantly in 2001 through the acquisition of Aventis CropScience, to less than 10 billion euros by the end of 2002.

In fiscal 2001, PolymerLatex generated sales of 344 million euros with about 730 employees. The joint venture, which was founded in 1996 by Degussa and Bayer, produces latex products in the paper, carpet/moulded foam and speciality applications fields, and holds a leading position among latex suppliers. PolymerLatex has been able to expand its leading market position even further over the past few years thanks to significant investments in its five European production sites, and continuous development of customized products.

Soros Private Equity Partners ("Soros") is a global private equity investor which, together with its affiliates, currently manages in excess of US-Dollar 4 billion of equity capital. Soros has announced that it intends to develop PolymerLatex's operations in the coming years and will consider possible add-on-acquisitions to consolidate its market share.

Bayer is an international, research-based group with major businesses in health care, crop science, polymers and specialty chemicals. For 2001, the group recorded sales of 30.3 billion euros. Capital expenditures totaled 2.6 billion euros in 2001 and 2.6 billion euros were invested in research and development. The total number of employees worldwide at the end of September 2002 amounted to about 123.500. For more information visit

2003/06/19 バイエル

 バイエル ケミカルズ ジャパン株式会社を7月1日に設立

 バイエル株式会社(本社:東京都港区、社長:ミヒャエル・ポートフ)は、2003年7月1日付で、同社の基礎・精密化学品およびスペシャリティ製品等の化学製品を取り扱う事業部門を新設分割の方法により、全額出資子会社としてバイエル ケミカルズ ジャパン株式会社を設立する。代表取締役社長には、バイエル(株)日本・韓国バイエル ケミカルズ代表のエッカード・ベンデロートが就任する。なお、新会社の所在地はバイエル(株)に同じ。


 また、バイエル(株)が所有している豊橋事業所(愛知県豊橋市)を従業員を含めバイエル ケミカルズ ジャパン(株)に移管する。同事業所は、物流センターおよび顧客技術サービスセンターとして、紙パ用化学品、繊維加工用化学品、およびイオン交換樹脂などの試験施設を擁している。

4事業部門の再編の一環として実施される。本改革は、ヘルスケア、農薬、高分子材料、化学品の各事業の独立性の拡大と世界市場における競争力の維持・強化を目的としたもの。なお、バイエルグループ(ドイツ)においても本年中に化学品事業を担うバイエル ケミカルズ社が独立子会社として発足し、ドイツ・バイエル社が持株会社として運営する予定。

 バイエルグループの化学品事業の売上は、33億ユーロ(2002年)で、すでに世界的なリーダーとしてのポジションを確立している。一方、日本における化学品事業グループは、基礎・精密化学品およびスペシャリティ製品等の化学製品を取り扱う化学品事業部門とH.C.スタルクで構成されており、売上は330億円(2002年)。化学品事業部門は、11ユニットで構成されており、中間体製品、添加剤、着色剤や技術ソリューションを多岐に渡る産業に提供している。バイエルの化学品事業グループの商品や業績の詳細はホームページ (英語)にて閲覧可能。

 H.C. スタルク社は、ドイツ・バイエル社の関連企業であり、世界各地で耐熱性金属やスペシャリティ製品の生産・販売をしている。日本においては、日本のバイエルのグループ企業であるスタルク ヴイテック(株)が同事業を引き続き行なう。

バイエル ケミカルズ ジャパン株式会社概要
  会社名称 バイエル ケミカルズ ジャパン株式会社(Bayer Chemicals Japan Ltd.)
  設立日 2003年7月1日
  資本金 4億円 (バイエル株式会社100%出資)
  従業員数 61名
  事業内容 有機・無機化学品原材料の輸入・販売・スペシャリティ製品に関する研究
  本社 東京都港区高輪4丁目10番8号
  事業所 豊橋事業所(愛知県豊橋市)
顧客技術サービスセンター(兵庫県姫路市)--- 皮革用化学品ラボ
  役員 代表取締役社長  エッカード・ベンデロート
取締役        ミヒャエル・ポートフ
取締役        ブルース・オルソン


China Chemical Reporter 2003/7/29

Bayer Plans to Invest in the Construction of a HDI Project in Shanghai

Bayer of Germany has signed with Shanghai Chemical Industry Development Zone an MOU on the construction of a 30 000 - 50 000 t/a HDI (hexamethylene diisocyanate) project in the next 3 years. Bayer is one of the first chemical giants launching projects in Shanghai Chemical Industry Development Zone and has so far put a total investment of over US$3.0 billion. The coating project starting construction by Bayer in January 2001 has been completed and put on stream and the annual output value of the project can hopefully reach RMB150 million. The polycarbonate project jointly funded by Bayer and Shanghai Chlor-alkali Chemical Industrial Co., Ltd. will start construction in the fourth quarter this year. Preparations of the MDI/TDI project that has already been approved are also under way. Bayer has a keen interest in the increasing market of high-tech chemical products in China and intends to make further investments in the integrated base in Shanghai. According to the MOU, Bayer will construct a 30 000 - 50 000 t/a HDI unit in the compounds of its coating plant and put the project on stream in 2006. HDI is a major raw material for coatings and adhesives produced in Bayer Coating Co., Ltd.

August 11, 2003 Bayer Polymers

Asian center for high performance coating raw materials
Bayer Polymers plans large-scale investments at its Caojing, China, site

Bayer Polymers, a division of Bayer AG, plans to expand its Caojing site near Shanghai, China, making it Bayer Polymers' most important production facility for coating raw materials in the Asia Pacific region. Production plants for
aliphatic (脂肪族) and aromatic polyisocyanates as well as the monomer hexamethylene diisocyanate (HDI) will be constructed in three phases at the Shanghai Chemical Industry Park. This project is being managed by Bayer Coatings Systems Shanghai Company Limited (BCSS), a wholly-owned Bayer subsidiary that develops, produces and markets raw materials for coatings and adhesives and also provides associated technical services.
"The demand for raw materials for the manufacture of high performance polyurethane coatings is growing strongly in this region. With this large-scale investment program, we aim to optimally exploit the excellent market opportunities there," says Dr. Joachim Wolff, Senior Vice President of Global Operations Base and Modified Isocyanates (BMI) at Bayer Polymers, "We expect our coating raw materials business to continue its outstanding performance because the coatings formulated from these products satisfy highest requirements with respect to appearance, chemical resistance, mechanical strength, lightfastness and weather stability.

In April 2003, a plant with an annual capacity of 11,500 tons was brought on line for the production of the
Desmodur® N line of aliphatic polyisocyanates, a segment in which Bayer Polymers holds a leading position. These raw materials are used primarily in the formulation of general industrial and automotive refinishing coatings, as well as coatings for plastics.

A production plant for the
Desmodur® L line of aromatic polyisocyanates is currently under construction. These raw materials have proved ideal for the formulation of high performance polyurethane coatings, e.g. for wood and furniture. With the start of operation of this plant in late 2004, Bayer Polymers will have a total capacity of 11,000 tons for Desmodur® L products at the Caojing site, enabling Bayer Polymers to maintain its strong position in the field of low-monomer raw materials for these coating systems. Bayer Polymers' goal is to be the first local producer of low-monomer TDI adducts in support of a Chinese government initiative to reduce the free TDI content in wood and furniture coating systems for interior applications.

The third project is the construction of a plant for the production of
HDI, which is used as a raw material for aliphatic polyisocyanates. The plant will ultimately have a total capacity of 50,000 tons, with 30,000 tons available by 2006. Capacity can be expanded by roughly 20,000 tons in a second phase of construction if warranted by market growth in the region.

2003102日 バイエル株式会社

バイエル ヘルスケア社、バイエル ケミカルズ社、バイエル テクノロジー サービス社が独立

 バイエル(本社:ドイツ、レバクーゼン、社長:ヴェルナー・ヴェニング)は、2003930日、バイエル ヘルスケア社、バイエル ケミカルズ社、およびバイエル テクノロジー サービス社が、商業登記を終え、法的に独立子会社になったことを発表した。これは、2002年よりバイエルグループ全体で始まった組織改革の一環であり、2003年末までには事業グループのバイエル ポリマーズと、サービス事業部のバイエル ビジネス サービスおよびバイエル インダストリー サービスも独立を完了する予定。すでに2002101日には、バイエル クロップサイエンス社が独立子会社として事業を開始している。


 バイエル ヘルスケア社は、医療用医薬品、バイオロジカルプロダクト、コンシューマーケア、診断薬、動物用薬品の
5分野から成り、世界各地でヘルスケア事業を展開している。バイエル ヘルスケアは現在、世界各地に約34,000人の社員を擁しており、2002年の売上高は94億ユーロ。バイエル ヘルスケア社のロルフ・クラッソン社長は、「バイエル ヘルスケアは、人間と動物の健康にかかわる広範な製品群を提供している。当社の強みは、高い競争力を持つ広範な製品ポートフォリオだ。当社の5部門中4部門がそれぞれの市場で上位5社に入っている。当社は良好なスタート地点に立っており、ここからさらに強力なヘルスケア事業を構築していく」と述べている。

 バイエル ケミカルズ社は、革新的なスペシャリティ化学品の大手企業であり、世界
130地域に約14,500人の社員を擁している。バイエル ケミカルズには既存のバイエルの化学品事業と子会社ウォルフ・ワルスローデが含まれており、H.C.スタルク社の事業運営も担当する。製品群は、染料、紙・パルプ用化学品、皮革用化学品、繊維加工用化学品、機能性化学品、医薬品・農薬向け中間体など多岐にわたる。2002年の売上高は33億ユーロ。バイエル ケミカルズ社のウルリッヒ・ケム社長は「当社は、技術を革新し、常に前進する企業である。高品質の製品と第一級の顧客サービスによって、当社は長期的な成功の基盤を固めつつある」と語っている。

 バイエル テクノロジー サービス社は世界中で事業展開しており、化学品および医療用医薬品生産施設の開発、計画、建設、そして工程の最適化を担当している。ドイツ、レバクーゼンに本社を置き、テキサス州ベイタウン(米国)、メキシコシティ(メキシコ)、サンパウロ(ブラジル)、上海(中国)に地域事務所を設置している。全従業員数は
2,300人。2002年の売上は69,000万ユーロ。バイエル テクノロジー サービス社のウォルフラム・ヴァーグナー社長は「我々は、技術革新と費用効果の高いソリューションを提供し、顧客の世界的な利益の確保と拡大を手助けすることを目的としている。この新会社の設立により、約2,300人の技術者と科学者が数十年にわたって蓄積してきた経験と専門知識が、さらに広範な社外の顧客にも利用可能となった」と述べている。


日本のバイエルは、ヘルスケア、農薬、高分子材料および化学品事業を展開している。 日本におけるバイエルグループ全体の
2002年の売上げは2,110億円で、従業員数は約2,900名。 バイエルにとって、日本は世界第3位の市場。


日本経済新聞 2003/11/8              発表

独バイエル 中核の化学事業分離 経営資源、医薬などに集中


November 7, 2003

Werner Wenning continues systematic realignment:
Bayer plans stock market flotation for chemicals activities and strategic refocus of health care business

Supervisory Board approves Management Board plans /
Focus on core businesses should enhance Bayer's competitiveness /
New company to be positioned among Europe's leading chemical enterprises /
Pharmaceuticals business to be retained as stand-alone solution

Following its successful reorganization, the Bayer Group intends to maintain its focus on its core businesses and in the future concentrate on health care, nutrition and innovative materials. For this reason, Bayer Chemicals (excluding H.C. Starck and Wolff Walsrode) is to be combined with certain parts of the polymers business in a new company with the provisional name "NewCo". The aim is for this company to be listed on the stock market under a new name by early 2005 at the latest. The Supervisory Board approved these plans of the Group Management Board at its meeting today. CEO designate of the new company is Dr. Axel Claus Heitmann (44), currently a member of the Executive Committee of Bayer Polymers and head of that company's Asia region, headquartered in Shanghai.
"Both Bayer and NewCo will benefit from the split, because a stock market listing will be highly attractive for both shareholders and employees," explained Bayer CEO Werner Wenning. "Following the separation, Bayer with sales of around EUR 22 billion will be able to focus more closely on the core businesses in which we have excellent technologies, strong market positions and above all growth areas that we intend to further strengthen by pooling all our resources. In this way, we aim to safeguard the success of our company in the long term and generate additional value. Bayer's reorganization was a key requirement for this significant step. Equally, we will be safeguarding the future of our chemicals business because, as an independent company, NewCo will be able to respond faster and more flexibly. In this new scenario, chemicals and polymers will be the core businesses and therefore the top priorities of the company's new management team."

In the future Bayer aims to concentrate all its financial and management resources on developing and expanding its core activities in health care, nutrition and innovative materials, which are predominantly research-intensive areas. Wenning sees high growth potential in these areas but also a corresponding need for investment. "This means we do not have sufficient resources available to maintain or enhance the market positions of our chemicals business or all of our polymers activities," said Bayer's CEO. The separation should trigger the necessary entrepreneurial impulses and create the conditions for optimizing the strategies of each company according to their different business needs.

Bayer's wealth of knowledge with respect to humans, animals, plants and materials, coupled with the respective products, will provide the foundation for sustainable growth in the long term in the promising markets in which Bayer plans to specialize. Following the reorganization, Bayer will have three operating subgroups: Bayer HealthCare, Bayer CropScience and Bayer MaterialScience.

Growth will come primarily from products containing newly researched active ingredients, from the consumer healthcare business and from growth in Asia. However, contributions to value creation should be achieved by the Group-wide utilization of technology platforms, nanotechnology and the expansion of biotechnology and genetic engineering as key innovation drivers.

Biotechnology is used not only by CropScience to achieve sustainable qualitative improvements in food crops and higher yields, but also to open up a range of new applications in other areas such as gene-based diagnostics.

Bayer's new realignment also includes repositioning the Pharmaceuticals business. "We have examined all the options for this business especially the possibility of partnerships. We found that none of these solutions would have adequately reflected the value of our Pharmaceuticals business. In our view, they would not have offered a value-creating alternative," explained Werner Wenning. "We therefore intend to focus on our own strengths and steer our Pharmaceuticals Division with significantly modified structures towards a successful future." Bayer will concentrate its research effort on the therapeutic areas where it already plays a leading role and has developed successful products: anti-infectives, cardiovascular (including diabetes and obesity) and urology. Bayer also has a number of promising product developments in the oncology (cancer) field.

"We intend to position our Pharmaceuticals Division as a mid-size European pharmaceuticals business because we are convinced that this will generate the greatest value for our shareholders," stated Wenning. In the future, the division's activities will be focused more strongly on Europe, though without neglecting the important markets in the United States and Asia. According to Wenning, considerable progress has already been made in restructuring Pharmaceuticals. Successful new product launches have given grounds for optimism. For example, sales of LevitraR, Bayer's treatment for erectile dysfunction, are very encouraging. Also, major progress has been made in the area of cancer research. A raf kinase inhibitor for the treatment of advanced renal cell carcinoma, developed in collaboration with U.S. company Onyx, has now entered phase III clinical trials.

Wenning also sees particular opportunities for growth in the consumer healthcare business. Bayer's Consumer Care, Diagnostics and Animal Health divisions hold strong or very strong positions worldwide. The company intends to further expand these activities.

The CropScience business units Herbicides, Insecticides, Fungicides and Seed Treatment hold excellent positions, and the aim is to grow faster than the market in these areas. Environmental Science is the market leader in the supply of pest control products for the home and garden. The Bio Science unit is a pool of impressive expertise in the field of biotechnology for which experts predict annual growth rates of 15 percent.

In MaterialScience, Bayer holds global leadership positions in polyurethanes, polycarbonates and coating raw materials. It has access to internationally acknowledged leading-edge technologies and a wealth of expertise acquired over many years. It is intended to continue expanding the growth areas of innovative plastics and coatings materials with a special investment focus on the growth markets of Asia. In China alone, Bayer is currently building or planning several new production facilities. The MaterialScience subgroup will in future also include the subsidiaries H.C. Starck and Wolff Walsrode.

In addition to these three operating subgroups, the three service companies will also remain within the Bayer Group. These companies will also perform services for NewCo. Employees of the service companies whose work centers on areas that will be part of NewCo are to be transferred to NewCo.

With sales of EUR 5.6 billion and a workforce of around 20,000, NewCo will rank among Europe's leading chemicals suppliers, occupy leadership positions in more than two thirds of global market segments and be a technology leader in manufacturing. "Independence will trigger strong entrepreneurial impulses, enabling NewCo to enhance the competitiveness of its production technology, too, and generate above-average growth and value," said Wenning.

Independence from Bayer should put NewCo in a position to utilize capital resources more efficiently for the enhancement of its competitiveness and to seek partners or investors at its discretion. The new structure will also make it easier to focus management resources on the specific needs of the chemicals business, conform structures and processes to the requirements of the chemical industry and activate niche markets utilizing new business models. The aim is to continue to grow through a stronger focus on innovation, efficient use of resources and targeted expansion of attractive specialty applications.

NewCo will have a broad-based portfolio of around 5,000 products covering basic, specialty and fine chemicals as well as polymers. These products include: intermediates for the manufacture of active ingredients for pharmaceuticals and crop protection products; material protection products; chemicals for the leather, textile and paper industries; ion exchange resins for water treatment applications; inorganic pigments for coloring concrete and plastics; polymer additives such as flame-retarding agents and plasticizers; solid rubber and rubber chemicals for the rubber and tire industries; ABS (styrenics) and semi-crystalline thermoplastics which are used primarily in automotive engineering, as well as for the manufacture of covers and housings. NewCo will have a global presence with production facilities and sales organizations in 40 companies and 20 countries.

November 26, 2003

Media briefing on November 26, 2003, Shanghai, China

"Photo: Bayer MaterialScience"


2003/12/15 Bayer


(asset impairment charges) を計上することになった。この費用は、製品群の戦略的な再編、分社化が決定した新会社(化学品事業と一部の高分子材料事業より構成)の株式上場計画、並びに今後のバイエル マテリアルサイエンス事業グループの経営条件の変化と関係している。なお、金利・税金支払い前収益(EBIT)へのこれら特別項目の影響は約20億ユーロになると予想されており、営業外収益は約2億ユーロ減少する見込み。


バイエル ヘルスケア事業グループは約5億ユーロの資産減損費用を計上する予定で、その一部は医療用医薬品研究施設の統合と関連している。




December 11, 2003 Bayer

Bayer and DuPont expand leading position in engineering thermoplastics
Dedication of world-scale plant for the production of polybutylene terephthalate (PBT)
Operator is the joint venture DuBay Polymer GmbH / Total investment 50 million euros / Annual capacity: 80,000 tons

With the dedication of a world-scale plant for the production of polybutylene terephthalate (PBT) in Hamm-Uentrop, Germany, Bayer and DuPont are building on their position as leading manufacturers of engineering thermoplastics. With an initial capacity of 80,000 tons per year, the plant is the biggest of its kind in the world. It will be operated by DuBay Polymer GmbH, a joint venture between Bayer and DuPont. The two companies have together invested some 50 million euros in the plant, in which 61 people are employed.
For a company to thrive in today's highly competitive market, it must be able to supply top-quality PBT at competitive prices. In Europe, this is only possible with large world-scale plants and state-of-the-art production technology. "Neither of the two companies, DuPont or Bayer, can make adequate use of such a plant immediately on their own, despite the favorable growth forecasts," said Dr. Hagen Noerenberg, head of Bayer Polymers, at the dedication ceremony. "With the jointly operated facility, both partners will strengthen their positions in the keenly contested global market for PBT," said Ferdinand Bauerdick, DuPont´s Director Europe Engineering Polymers, who is also responsible for the global polyester business of DuPont. Both companies use the straight resin from the production facility and compound it into products for their PBT ranges Crastin® in the case of DuPont, and Pocan® in Bayer's case.

In 2002, some 140,000 tons of the polymer were processed in Europe. Global demand for PBT will grow in the next few years at an above-average rate of somewhere between six and eight percent a year.

One of the strengths of PBT is its broad, well-balanced property profile. The high-tech plastic is noted among other things for its good heat and chemical resistance, its high stiffness and its ease of processing. It also has outstanding electrical insulating properties, produces parts with an excellent surface finish and can be readily combined with other plastics to produce blends.

The material has a particularly promising future in the automotive and electrical/electronic industries. These two segments are the main customers for PBT, accounting together for around 80 percent in more or less equal shares. Products for medical, sport and leisure applications are also made from this high-performance plastic.

The new production plant at DuPont's Hamm-Uentrop site is integrated entirely into the infrastructure of the Chemical Parkfrom the energy supply to the traffic links and raw material logistics. The new PBT plant, which was built in just under two years, also sets new standards in terms of environmental protection and occupational safety. For example, no solvents are used to manufacture the plastic, and the only by-product, methanol, is fed back completely into the production process. "Virtually 100 percent of the raw materials go into the desired product. In this way, we conserve valuable resources," said Dr. Hubert Fink, chairman of the members committee of DuBay Polymer GmbH.

March 22, 2004 Bayer CropScience

Bayer CropScience to purchase Crompton's share of Gustafson seed treatment business
Acquisition for 124 million US Dollar in North America and Mexico

Bayer CropScience LP in the U.S. and Bayer CropScience Inc. in Canada today signed agreements to purchase Crompton Corporation's 50 percent share of the Gustafson seed treatment business in the United States, Canada and Mexico [NAFTA] for the purchase price of U.S.$124 million in cash.
The action would give Bayer CropScience, which already holds a 50 percent share of the U.S. and Canadian Gustafson joint ventures,
full ownership of Gustafson's NAFTA business, subject to customary closing conditions. The transaction is expected to close by the end of the first quarter.

Gustafson manufactures and markets seed treatment products and related equipment. Based in Plano, Texas, and Calgary, Canada, the company employs approximately
250 people in the NAFTA region. In 2003, Gustafson sales were approximately U.S.$130 million.

Purchase of the Gustafson seed treatment business would allow us to participate directly in this increasingly important segment of the NAFTA crop protection markets,said Emil Lansu, President & CEO of Bayer CropScience LP and head of Bayer CropScience for the NAFTA region. According to Lansu, the acquisition would give Bayer CropScience the benefit of the full range of Gustafsons products, including certain products from third parties, which would continue to make up a key component of the Gustafson product portfolio. We presently have several strong seed treatment products,Lansu added. With the Gustafson purchase we look to more fully realize the potential of this business while enhancing our ability to provide solutions for growers.

Crompton Corporation, with annual sales of $2.2 billion, is a producer and marketer of specialty chemicals and polymer products and equipment. Additional information concerning Crompton Corporation is available at

Bayer CropScience, a subsidiary of Bayer AG with annual sales of about EUR 5.8 billion (2003), is one of the world
s leading innovative crop science companies in the areas of crop protection, non-agricultural pest control, seeds and plant biotechnology. The company offers an outstanding range of products and extensive service backup for modern, sustainable agriculture and for non-agricultural applications. Bayer CropScience has a global workforce of about 19,000 and is represented in more than 120 countries, ensuring proximity to dealers and consumers.

May 4, 2004 Bayer

Agreement signed to build a plant for the coating raw material HDI
Bayer: Investments to strengthen growth in China

In the presence of Gerhard Schroder, the German Chancellor, and Wen Jiabao, the Chinese Premier, Werner Wenning, the Chairman of the Board of Management of Bayer AG, and Prof. Gottfried Plumpe, a member of the Board of Management of Bayer MaterialScience AG, signed an agreement with Ruan Yanhua, President of the Shanghai Chemical Industry Park Corporation, to build a world-scale production plant for the coating raw material HDI (hexamethylene diisocyanate). The ceremony was held during the third German-Chinese high-technology dialogue forum on May 4, 2004, in Berlin.
The HDI project involves a total capacity of up to
50,000 t/y and an investment of some USD 100 million. Construction of the new facility is scheduled to begin in fall 2004. HDI is a precursor for aliphatic polyisocyanates, which serve as raw materials for high-grade polyurethane coating systems. Such systems are used predominantly for automotive, industrial and plastics coatings. Bayer is the market and technology leader in this field.

"China is already one of our most important markets," said Management Board Chairman Wenning during the signing of the agreement. "China's importance for the chemical and pharmaceutical industry will increase further in the coming years. Bayer wants to play a leading role in the economic development of the People's Republic. With our investments in Caojing, we are creating ideal conditions for strengthening our growth in this key market."

Over the next few years, total investments of some USD 3.1 billion are scheduled for the integrated production site at Caojing near Shanghai. Of this, Bayer will spend some USD 1.8 billion on new facilities for polymer production - construction work has already begun in some cases. Other projects worth a total of USD 1.3 billion are also planned, but these will be tackled later.

With the building of large capacities for polyisocyanates, Caojing will become the main production site for Bayer MaterialScience's coating raw materials in the Asia-Pacific Region. Initial production capacity for the precursor HDI will reach 30,000 t/y by 2006. Depending on the way the market develops in the region, capacity could be extended by a further 20,000 t/y as part of a second construction phase. Since April 2003, coating raw materials in the Desmodur
® N range have been produced in a neighboring plant that has an annual capacity of 11,500 t. At the end of 2004, a production facility for Desmodur® L with a capacity of 11,000 t/y is also due to go on stream.

Also at the Caojing site, construction has started on a new world-scale production plant for Makrolon
® polycarbonate. The intention is that the plant will go on stream in 2006, and will gradually be expanded to reach a total capacity of 200,000 t/y - in line with market developments. A further focus of investment is the construction of world-scale production facilities for the two polyurethane raw materials, MDI and TDI, which are used predominantly in the manufacture of polyurethane foams. The plants for MDI and TDI are scheduled to begin production by 2008 and 2009 respectively.

With sales of around EUR 1.1 billion in 2003, the Greater China country group is Bayer's second-largest single market in Asia after Japan. The company employs more than 2,700 people in Greater China and is also represented there by a total of 24 firms. Eleven manufacturing companies from all Bayer's areas of business are now producing in the region, with the result that an increasing proportion of sales is being covered by local production.


July 19, 2004 Bayer

Bayer to Acquire Roche Consumer Health

Acquisition creates global consumer health care company that will rank among top three worldwide / Acquisition price EUR 2.380 billion including U.S. joint venture
With the acquisition of Roche Consumer Health, Bayer is going to extend its portfolio of long-standing brands for commercial success.

Bayer announced today that it has agreed to acquire Roche Consumer Health. By acquiring this business Bayer will become one of the top three over-the-counter (OTC) consumer health companies worldwide. Additionally, Bayer will acquire Roche's 50 percent share of the 1997
Bayer/Roche joint venture in the U.S., (an element not included in Roche's original offering) and five Roche production sites in Grenzach (Germany), Gaillard (France), Pilar (Argentina), Casablanca (Morocco) and Jakarta (Indonesia). The OTC business of the Japanese company Chugai, in which Roche has a majority stake, is not included. The acquired business has yearly sales of around EUR 1 billion. The EUR 2.380 billion transaction is subject to approval by relevant antitrust authorities.
It is our intention to further strengthen Bayers OTC business to become world leader, and with this acquisition we make another large step towards this goal,said Werner Wenning, Chairman of the Board of Management of Bayer AG. By combining the two businesses we can realize significant synergies. Additionally, the acquired business is of high value - the combined product portfolios are very complementary and contain strong trusted brands. The acquisition also provides growth and attractive profit margins in an interesting and fast developing part of the health care market -- one which is characterized by increasing consumer interest in overall health and self-medication. This is a good opportunity for our products.

Bayer HealthCare's Consumer Care Division and Roche Consumer Health share a heritage of building on their long-standing brands for commercial success. Both have a number of significant analgesic, dermatological, gastrointestinal and nutritional brands that offer outstanding growth potential across the globe. Combined brand equities include such well-known brands as Bayer's Aspirin®, Alka-Seltzer®, Midol® and One-A-Day® and Roche's Aleve®, Bepanthen®, Berocca®, Flanax®, Redoxon®, Rennie®, and Supradyn®.

Both companies have a strong market presence in Europe and the Americas and the move also builds greater presence for Bayer HealthCare in the growing Asia-Pacific region.
Through this acquisition we intend to leverage the capabilities, reputation, and strong brands of both companies to create a world leading OTC company,said Arthur Higgins, chairman of the Executive Committee of Bayer HealthCare. The new organization will be uniquely positioned to exploit the growth potential in the OTC-market and emerge as a partner of choice for future Rx/OTC-switches.

Assuming approval from the relevant antitrust authorities and subsequent closing of the transaction by the turn of the year 2004/2005, after one time charges of about EUR 300 million Bayer expects an EPS impact (earnings per share) of 0.25 EURO /share in 2005 and a positive impact on results from 2006 forward. The synergy potential is estimated at approximately EUR 100-120 million. It is planned to realize the synergy potential gradually over the next three years.

Bayer plans to finance the acquisition out of existing facilities. Bayer had liquid assets of EUR 2.6 billion at the end of the first quarter 2004 and thus a sound basis for financing the transaction.

The combined company will have sales of EUR 2.4 billion and 6,700 employees in 120 countries. It will be headed by Gary Balkema, currently president of Bayer HealthCare
s global Consumer Care Division and have its global headquarters in Morristown, New Jersey, U.S.A. Mr. Balkema is an experienced Consumer Care executive who has successfully enabled Bayers consumer health business to consistently outperform the OTC market for the past five years. The European headquarters will be in Switzerland in the Basel area. Research and development for the new organization will be situated at Bayer Consumer Care headquarters in Morristown and at the Roche Consumer Health site in Gaillard, France.

About Bayer
Bayer is a research-based, growth-oriented global enterprise with core competencies in health care, nutrition and high-tech materials. In 2003, Bayer employed some 115,400 people and had sales of EUR 28.6 billion. The capital expenditure budget for the current year is EUR 1.8 billion, the R&D budget EUR 2.3 billion. The Bayer Group is committed to the principles of sustainable development ? with economic growth, ecological integrity and social responsibility accorded equal priority in its corporate activities throughout the world. For more information on Bayer go to

About Bayer HealthCare
Bayer HealthCare, a subgroup of Bayer AG with sales of approximately EUR 8.9 billion in 2003, is one of the world's leading, innovative companies in the health care and medical products industry.
The company combines the global activities of the divisions Animal Health, Biological Products, Consumer Care, Diagnostics Professional Testing Systems and Diagnostics Self Testing Systems and Pharmaceuticals. 34,600 people are employed by Bayer HealthCare worldwide. Bayer Consumer Care, a division of Bayer HealthCare, is headquartered in Morristown, N.J. Bayer Consumer Care is among the largest marketers of over-the-counter medications and nutritional supplements in the world. Some of the most trusted and recognizable brands in the world today come from the Bayer portfolio of products. For more information on Bayer HealthCare, go to

About Roche
Headquartered in Basel, Switzerland, Roche is one of the world
s leading innovation-driven healthcare groups. Its core businesses are pharmaceuticals and diagnostics. Roche is number one in the global diagnostics market and is the leading supplier of pharmaceuticals for cancer and a leader in virology and transplantation. As a supplier of products and services for the prevention, diagnosis and treatment of disease, the Group contributes on a broad range of fronts to improving peoples health and quality of life. Roche employs roughly 65,000 people in 150 countries. The Group has alliances and research and development agreements with numerous partners, including majority ownership interests in Genentech and Chugai.

Alka-Seltzer, Aspirin, Midol and One-A-Day are registered trademarks of Bayer AG.
Aleve, Berocca, Flanax, Redoxon, Rennie and Supradyn are registered trademarks of F. Hoffman-LaRoche Ltd.

16 September 1996 Roche

Roche and Bayer to form an OTC joint venture in the United States

Roche Holding Ltd., Basel, Switzerland and the US subsidiary of Bayer AG, Leverkusen, Germany, have entered into a letter of intent to form a 50-50 joint venture to market several over-the-counter (OTC) drugs in the United States.
Subject to the approval of the relevant authorities, the joint venture will combine the companies' US OTC businesses in analgesics (except for Bayer Aspirin) and women's health. Brands included in the joint venture will be Roche's Aleve analgesic and Femstat 3 vaginal yeast infection treatment and Bayer's Actron and Vanquish analgesics, Midol menstrual pain reliever and Mycelex-7 vaginal yeast infection treatment.
Bayer will be responsible for sales and marketing of the joint venture products within its overall Consumer Care portfolio. Financial terms of the agreement were not disclosed.
In addition to Bayer Aspirin, the joint venture will not include other leading Bayer brands such as Alka-Seltzer, Alka-Seltzer Plus and One-A-Day and Flintstones vitamins.
Anthony J. Jamison, head of Roche Consumer Health, Roche's worldwide selfmedication business, said the agreement with Bayer is "an excellent opportunity for Roche to build on the success already gained with Aleve and Femstat-3 in the United States and to develop a substantial OTC presence in the US market. We are very pleased to join forces with a strong partner in those segments of the OTC market where Roche has leading products.

"With this joint venture, we will further strengthen Bayer's presence in the US OTC marketplace,said Werner Spinner, head of Bayer's worldwide Consumer Care Business Group. "Bayer will now be a contender for third place among the nation's largest OTC health care marketers and will compete even more significantly in the US OTC analgesic market.
A committee with an equal number of members from each company will exercise joint effective control of the venture. Operational management will be contracted by the joint venture to Bayer Corporation Consumer Care Division, based in Morris Township, New Jersey.
This new agreement follows the June 1996 acquisition by Roche of Procter & Gamble's 50 percent stake in a 50:50 joint venture. In this agreement, Procter & Gamble had marketed Roche's Aleve and Femstat 3 brands in the United States.
With the new joint venture, marketing and distribution services will be transferred from Procter & Gamble to Bayer, with Procter & Gamble maintaining responsibility for professional selling until the end of 1997. "This process will be non-disruptive and transparent to our trade and retail customers," explained Werner Spinner. "We will begin working immediately to ensure a smooth transition and expect the transfer to be completed by the end of the year."

2004/09/13 Bayer



 また両社は、日本におけるシェリング・プラウ社の循環器系疾患治療薬ゼチア(R)の将来的な共同販売についても合意しました。さらに、バイエル ヘルスケア社の医療用医薬品事業部は、米国を拠点としたがん領域のグローバル事業部を新たに設立し、米国の同社組織を高収益で専門性の高い製品とバイオテクノロジー製品に特化するよう方向転換させます。

 「一般消費者向けビジネスでの拡大を狙ったロシュ社の一般用医薬品事業買収に続き、バイエル ヘルスケア社は新たな戦略的節目を迎えました。シェリング・プラウ社との提携により、両社はお互いが得意とする地域での強みを生かすことができます。本提携により、米国におけるバイエルのコスト構造とリソースを調整して戦略的業績目標達成を可能にし、当社製品の潜在的可能性を更に引き出すことができます。同時に、日本での事業拡大を推進します」。




世界市場を担うがん領域の事業部を新たに設立し、その営業組織を構築します。このがん領域事業部はコネチカット州ウエスト・ヘブンに本部を置き、オニックスファーマシューティカル社と共同開発中の抗がん剤BAY 43−9006の承認取得および発売の準備を行います。進行性腎細胞がんの治療薬として臨床試験で有望な結果を示しているこの開発候補品は、現在第III相臨床試験が行われています(日本国内では第I相臨床試験)。今回の契約に基づき、バイエル社は米国および欧州の主要な市場でシェリング・プラウ社のがん領域製品の販売活動を一定期間行ないます。前立腺がん治療に使われるバイエルのヴィアデュール(R)もこのがん領域事業部で取り扱います。

 バイエル ヘルスケア社経営委員会代表のアーサー・ヒギンズは次のように述べています。「シェリング・プラウ社との提携は、重要な米国市場における私たちのプライマリーケア製品群の業績を高め、バイエル社医療用医薬品事業にコスト構造と利益率の改善をもたらします。また、がん領域のグローバル事業部を設立し、この重要な治療分野での基盤を築くなど、医療用医薬品事業の将来への投資能力を向上させることができます。」


 バイエル ヘルスケア社、米国医療用医薬品事業部でプライマリーケア以外の組織は、これまで同様ウエスト・ヘブンを本部とし、主に専門医が扱う高収益な専門領域の製品とバイオテクノロジー製品に集中します。がん領域の製品に加え、血友病治療薬コージネイト(R)と、開胸心臓外科手術で使われるトラジロール(R)が、その製品ポートフォリオです。



■バイエル ヘルスケア社について
 ドイツ・バイエル社の事業グループであるバイエル ヘルスケア社の年商は約89億ユーロに達し、ヘルスケア、医療製品業界における世界の主要企業の一つです。バイエルヘルスケア社は、バイエル社の関連事業(動物用薬品、バイオロジカル プロダクト、コンシューマーケア、診断薬、医療用医薬品)の世界規模の活動を統括しており、世界中で3万4,600人以上の従業員によって支えられています。全世界の人類と動物の健康を向上させるため、革新的な製品を開発・製造することがバイエルヘルスケアの使命です。私達の製品は、疾患の診断、予防そして治療を通じて、健康とQOL(クオリティ・オブ・ライフ)の向上に貢献します。

2004/12/13 バイエル

バイエル社、血漿分画製剤事業を米国投資会社 Cerberus社とAmpersand社に売却

−コージネイト®は、バイエル ヘルスケア社の製品として継続販売−


 本契約の内容には、バイエル ヘルスケア社バイオロジカルプロダクト事業部の血漿分画製剤事業に関連する製品、施設そして社員が含まれています。血友病Aの治療に使用される遺伝子組換え型血液凝固第VIII因子製剤コージネイト®は売却対象ではなく、バイエル ヘルスケア社の製品としてこれまでどおりに販売されます。

 「コージネイトFS®およびコージネイト®は、バイエル ヘルスケア社のポートフォリオの中で最も貴重で、戦略的にも重要な製品のひとつです。今後さらにビジネス再編を計る上で、この製品は長期戦略に不可欠で、それによって世界中の血友病市場でリーダーシップを発揮することができるのです」とバイエル ヘルスケア社経営委員会代表アーサー・ヒギンズ氏は述べています。


 「非常に幅広い製品パイプライン、卓越した製造技術、病原体混入防止に向けた安全性研究、患者さんに対する強い責任感をもつ会社へ投資できることを大変うれしく思います。この戦略の一環として、NPS Bio Therapeutics社は現在バイエル社へ血漿分画工程業務を提供しているPrecision Pharma Services社を統合する予定です。現行の経営陣との連携の下、新しい経営組織は、NPS Bio Therapeutics社の業界でのリーダーシップをさらに発揮していきます。医療従事者と患者団体へのより良いサポートを推進しながら、この事業を成長させ強化していきます」とCerberus社の統括メンバーで、NPS BioTherapeutics社の会長に就任するラリー・スターン氏は述べています。

【 ドイツ・バイエル社について 】

【 バイエル ヘルスケア社について 】
 ドイツ・バイエル社の事業グループであるバイエル ヘルスケア社の2003年総売り上げは約89億ユーロに達し、ヘルスケア、医療製品業界における世界の主要企業の一つです。バイエルヘルスケア社は、バイエル社の関連事業(動物用薬品、バイオロジカル プロダクト、コンシューマーケア、ダイアベティスケア、診断薬、医療用医薬品)の世界規模の活動を統括しており、世界中で3万4,000人以上の従業員によって支えられています。全世界の人類と動物の健康を向上させるため、革新的な製品を開発・製造することがバイエルヘルスケアの使命です。私達の製品は、疾患の診断、予防そして治療を通じて、健康とQOL(クオリティ・オブ・ライフ)の向上に貢献します。

【 Cerberus Capital Management, L. P.社について 】
 Cerberus Capital Management, L. P.社は、ニューヨークに拠点を置く1992年創立の民間投資会社で、140億ドル超える投資資産を管理しています。Cerberus社は、北米、欧州、アジアでの事業を含む、様々なビジネス分野において40社以上の経営権を保有しています。Cerberus社は、資産価値を重視する投資会社で、長期に渡る高収益力の業績を求め、自社とのパートナーシップによる収益性を追求します。

【 Ampersand Ventures社について 】
 Ampersand Ventures社は、Panie Webber社から分離した1988年創立の民間の株式投資会社で、積極的な事業提携を通じて資産価値の増やすことに注力しています。Ampersand社は、広範囲の技術産業の分野に渡って独自の投資戦略を追求します。会社の資産の大半は、売却会社、拡大融資、中規模の企業買収そして業績回復のための資本再構成のポートフォリオに投資されます。Ampersand社は、1995年から血液製剤事業積極的な投資を行っており、現在バイエル社へ血漿分画工程業務を行っているPrecision Pharma Services社の経営権を保有しています。

Miles' switch to Bayer adds to global identity

Keenan, Tim

Customers and employees of Bayer Corp. - formerly Miles and once Mobay - may need to take a couple of the company's aspirin tablets now that it has changed its name for the second time in a little more than three years.

The latest revision of the Pittsburgh, PA-based plastics supplier's nomenclature will give the company one worldwide name and a stronger position as the auto industry progresses toward globalization, says H. Lee Noble, president of Bayer's polymers division.

The Miles-to-Bayer switch comes five months after Miles acquires Sterling Withrop's North American over-the-counter drug business, including Bayer aspirin and the Bayer trademark. Mobay-Miles Miles always had been a subsidiary of Bayer AG, the German-based international chemical and health care company.

"Until we acquired the Bayer aspirin business we could not use the name in the U.S.," explains Mr. Noble, who adds that the company was known as Miles only in the U.S. and Canada."

Now Mr. Noble again must establish an identity for a new name. In January 1992 the company, which had been called Mobay since it was established in 1954, changed its name to Miles. He admits the frequent changes have caused a bit of confusion among customers, but believes this transition will be easier.

"There was some confusion for a while when we changed the name to Miles," Mr. Noble recalls. "We had the Mobay name pretty recognizable." He says it took about a year to get everyone acclimated to the new name then. That move was made because Miles had better global recognition at the time than Mobay.

"This change will be accepted more quickly in the auto industry because of the Big Three's "connections to the European industry," says Mr. Noble. "Globally, Bayer is an automotive name. Most of Detroit has recognized for years that we are a subsidiary of Bayer in Germany."

Bayer supplies raw materials for many automotive components including seat cushions, bumpers, interior pieces and exterior coatings. The company claims it's the world's largest supplier of polyurethane.

With the new name, Mr. Noble says the company will have a renewed global orientation "It's something you really have to work at," he says of the industry's globalization trend, which Bayer anticipated 15 years ago when it instituted its World Automotive Committee. "It takes a real effort to get that coordination, preventing working at cross purposes," he adds.

Mr. Noble says he's not concerned about the industry's recent slowdown. hi fact, he's excited about Bayer's potential to pounce on several industry growth opportunities.

"But even if (the market) does slow down more than we expect, our products are still taking a greater share of the materials market," he says. "The value of plastics will continue to grow."

Body panels, interiors, side-impact energy absorption and recycling are the most fertile ground for plastics industry growth, says Mr. Noble.

"We recognize the importance of recycling to the auto industry and have focused our research and development efforts on solving this challenge," he says.

Fruits of these efforts include a proprietary technology allowing polyurethane RIM scrap to be molded into new parts. The 1994 Jeep Renegade features a close-out panel molded completely of recycled RIM polyurethane. The part was compression molded from RIM scrap from Chrysler minivans and replaced a part originally made from new material.

Bayer believes the 100% recycle-content material will see future uses in fender liners, wheel-well liners, air ducts, air deflectors and other parts requiring strength but not a high-gloss surface.

The company's other primary recycling initiative is a process to recycle seat-cushion foam.

2005/11/22 バイエル




 「日本では、すでに全ての事業グループが極めて強固な基盤を確立しています」とヴェニングは 続けた。グループ総売上のうち最大の割合を占めるのは、ヘルスケア事業グループ(バイエルヘルスケア)であり、2005年1-9月期の同事業グループの売上は前年同期比5.6%増の730億円を計上した。これは日本のバイエルの売上のほぼ半分に相当する。ヘルスケア事業で最大の割合を占める医療用医薬品事業は、厳しい市況にもかかわらず、安定した成長となった。特に「アダラート(R)」、「グルコバイ(R)」、「バイアスピリン(R)」をはじめとする脳・心血管系リスクマネジメント製品が好調であった。ヘルスケア事業のダイアベティスケア、診断薬、動物用薬品も2005年1-9月期にそれぞれ27%、11%、17%という優れた成長率を達成した。

ヘルスケア部門は成長を遂げており、今後も市場成長率を上回る成長を達成できると確信しています」と述べた。10月には、広範な抗菌スペクトルを有すニューキノロン系抗菌剤「アベロックス(R)」の輸入販売承認を得た。呼吸器感染症のプライマリーケアに使用できる本製品の販売を行う塩野義製薬(株)は、年内の上市を見込んでいる。日本の経口抗生物質市場は、2004年現在で年商 約20億ユーロの規模を持つ。

 ヘルスケア事業をさらに強化する計画として、米国シェリング・プラウ社が開発したコレステロール吸収阻害剤「ゼチア (R)」を、日本の当局の承認後発売する予定である。シェリング・プラウ社とバイエル薬品との間で、日本における同製品の共同販売契約がすでに 締結されている。また、バイエルが開発中の製品には、例えば、新たな抗がん剤「ネクサバール(R)」、血栓症治療を目的とした経口直接作用型Xa因子阻害剤など非常に有望な製品が含まれているとヴェニングは説明した。


バイエルマテリアルサイエンス)は、2005年1-9月期において前年 同期比24.7%増という大幅な成長を達成し、売上は500億円となった。ポリカーボネートおよびポリウレタン市場、特にハイテク樹脂「マクロロン(R)」や硬質フォーム用原料MDIの市場において強い需要が見られ、その結果、原料費の高騰を背景に製品価格が上昇し、満足すべき事業展開となった。ヴェニングは、特に「マクロロン(R)」、塗料原料、発泡素材が今後も成長すると予測している。

 「バイエルには日本市場において長い成功の歴史があります」とヴェニングは強調した。バイエルが 日本で最初に事業を行ったのは1886年であり、1911年にはすでに最初の100%子会社を設立。2004年には日本で約2,500人の従業員を雇用し、14億4,900万ユーロの売上を達成した。バイエルは、ヘルスケア、農薬関連そして先端素材の分野において、全ての製品ポートフォリオを日本市場に提供している。技術革新はバイエルグループの最大の強みのひとつである。1990年以来、バイエルは約9億ユーロの研究費を日本に投じてきた。


 「バイエルは、アジア太平洋地域に非常に強い関心を抱いており、この地域がここ10年間の資本投資の焦点になります」とヴェニングは指摘する。1990年から2004年にかけて、アジア太平洋地域におけるバイエルグループの設備投資と研究開発費の総額は29億ユーロに及ぶ。バイエルは、より一層の成長を促進するために、この地域にさらに資源を投入する計画である。 2005年1-9月期において、すでに約1,400人の従業員が新規に採用されている。これは他の地域を上回る実績である。

中国である。バイエルは上海近郊のCaojing(カオジン)において、「マクロロン(R)」とポリウレタン原料の生産施設を中心に、2009年までに18億米ドルを投資する計画である。日本においては、世界第2位の医薬品市場であり、アジア最大の農薬市場であるために、ヘルスケアおよび農薬関連事業における革新的な 製品パイプラインの強化に重点を置く。ヴェニングは「バイエルは、グループ全体の売上高に占めるアジア太平洋地域の売上比率を2010年までに現在の17%から25%に引上げることを目指しています」と述べた。

バイエル 2001年11月2日


世界的なヘルスケア・化学グループであるバイエル(本社:ドイツ・レバクーゼン)は、中国における事業拡大のため、このほど中国・ソウケイ(Caojing)(上海近郊)の新生産基地に関する基本契約に調印した。総投資額は31億ドル(34億ユーロ)。ドイツ・バイエル社のCEOであるマンフレッド・シュナイダー社長は北京で、「世界市場で成功するには、一方では効率的な生産ネットワーク、もう一方では不可欠なクリティカル・マス(臨界量)が重要な要素になる。バイエルのソウケイ(Caojing)工場はその両方において大きな役割を果たすだろう。 このプロジェクトはアジアにおけるバイエルの大きな目標を達成するためのカギである」と述べた。




中国もバイエルのプロジェクトに関して特別な役割を担っていく。 中国のこの10年間の年平均成長率が17%ときわめて高く、バイエルの最も強力な成長市場の1つとなっている。バイエルは今後5年間に、売上を2000年水準の10億ドル(11億ユーロ)から少なくとも2倍以上に伸ばすことを目標としている。




塗料・着色材の製造である。バイエルは2008 年までに計1億1,000万ドル(1億2,200万ユーロ)を投資する。建設の第1段階では、ポリイソシアネートの生産施設(年産1万1,500トン)が建設される。操業開始は2003年の予定。その後、生産能力は年産2万トンに引き上げられる見込み。建設の第2段階では、原料となるHDIの生産ユニットも建設される。バイエルの100%子会社「バイエル塗料システムズ(上海)社」が2000年12月に事業免許を取得しており、このプロジェクトの運営にあたる。

年産5万トンの生産能力を持つ当初の生産ラインが2003年に操業を開始し、2006年にはフル稼働する。当プロジェクトの総投資額は4億5,000万ドル(5億ユーロ)で、原料となるビスフェノールAの生産施設と配合工場が含まれている。 このプロジェクトは、バイエルの新しい子会社「バイエル・ポリマー(上海)社」(バイエルが株式の90%、上海クロルアルカリ社が10%を保有)が運営にあたる。プロジェクトの事業免許は2001年9月に承認されている。 建設は2001年11月2日に開始する。

このプロジェクトは、バイエルの新しい100%子会社「バイエル・ポリウレタン(上海)社」の名称で運営される。総投資額は約11億ドル(12億ユーロ)で、年産38万トンのイソシアン酸塩工場が建設される。このうち 23万トンはMDI、15万トンはTDIである。ポリウレタン生産では、イソシアン酸塩に続いてポリオールが2番目に重要な生産品目である。ポリエーテルの生産量は年産28万トンの予定。




Bayer May 15, 2006

Bayer MaterialScience develops pioneering technology for the production of TDI

High-output and resource-saving production process / Significantly reduced investment and operating costs / First use on a world scale at the integrated production site in Caojing

Bayer MaterialScience AG has developed a pioneering technology for producing toluene diisocyanate (TDI), which reduces the investment costs involved in constructing production plants by 10 to 20 percent. Moreover, the technology reduces the energy consumption by one third and sets new safety standards. A pilot plant with an annual production capacity of 30,000 tons has been in operation in the Bayer Chemical Park in Dormagen for over a year. The new technology is scheduled to be used for the first time on a world scale at Bayer MaterialSciences Caojing site near Shanghai. The company plans to construct a fully integrated TDI production plant there with an annual capacity of 160,000 tons by the end of 2009. TDI is used worldwide for the production of flexible polyurethane foam, large quantities of which are used in upholstered furniture, mattresses and automotive seating.

The new technology is a quantum leap in our development of state-of-the-art production methods that offer even greater efficiency. It provides an innovative system of energy management and sets new standards in high-output, resource-saving production methods,says Peter Vanacker, head of the Polyurethanes Business Unit at Bayer MaterialScience. This enables us to support our customersgrowth long-term by providing top-quality products and to reinforce our leading role on the global polyurethane market with optimum cost structures. Following the success with the new technology, we will also considering using it when constructing TDI plants in Europe in the future.

In the summer of 2005, Bayer MaterialScience finished years of work on a consolidation process for TDI and its primary products and has since focused its production on integrated world-scale plants. The story is similar with methylene diphenyl diisocyanate (MDI), an important raw material for producing rigid polyurethane foam, which guarantees a highly efficient insulation effect. Bayer MaterialScience is currently constructing a world-scale production plant for MDI in Caojing with a capacity of 350,000 tons a year, which is due to commence operation in 2008. The inauguration of a splitter for recovering monomeric and polymeric MDI from crude MDI is already scheduled for fall of this year. It will boast an annual capacity of 80,000 tons.

With sales of EUR 10.7 billion in 2005, Bayer MaterialScience AG is one of the world
s largest polymer manufacturers. Its main fields of activity are the production of high-tech polymer materials and the development of innovative solutions for products used in many areas of everyday life. The main consumer sectors are the automotive, electrical/electronics, construction, sports and leisure industries. Bayer MaterialScience has production facilities at 40 sites around the world and a workforce of approx. 18,800. Bayer MaterialScience is part of the Bayer Group.

September 5, 2006 Bayer

Bayer CEO Wenning at the inauguration of new production facilities in Shanghai

China is of central importance to Bayer
Total capital expenditures of US$ 1.8 billion at the Shanghai Chemical Industry Park through 2009
Significant capacity expansions for polycarbonates, polyurethanes and coating raw materials
s largest capital expenditure project outside Germany

At a ceremony on Tuesday before 500 guests, Bayer inaugurated the new production facilities of the Bayer MaterialScience subgroup in Shanghai.
China is of central importance to Bayer in the Asia-Pacific region ? both as a production base and for our business strategy,said Management Board Chairman Werner Wenning, underlining the countrys significance for Bayer. The project at the Shanghai Chemical Industry Park represents a total capital expenditure volume of about US$ 1.8 billion through 2009, explained Wenning in the presence of numerous guests from politics, industry and the media: This is our biggest-ever project outside of Germany.

At the inauguration ceremony attended by leading representatives of the City of Shanghai, the entire Management Board of Bayer AG and journalists from Asia and Europe, Wenning said: The integrated Bayer site in Shanghai is developing into our biggest and most technically advanced production site in the entire Asia-Pacific region. In turn, this region ? and particularly China ? is one of the most important future markets for the Bayer Group, a market that is set to become even more significant and dynamic.Wenning said the newly inaugurated facilities of Bayer MaterialScience will add substantially to production capacities.

Bayer MaterialScience CEO Dr. Hagen Noerenberg described the remarkable perspectives offered by the integrated site:
In the future this site will supply customers throughout the region with approximately 900,000 tons of plastics products a year. Our long-term commitment to the Chinese market and our customers here is a strategic cornerstone of our activities. We aim to play a leading role in advancing the Chinese plastics industry through our products, technologies and employee training.

In these respects the company expects the new production facilities to play a key role. Dr. Jurgen Dahmer - Senior Bayer Representative for Greater China and Senior Representative for Bayer MaterialScience in China, and thus landlordof the Shanghai site - presented the details of these plans in his welcoming address. The existing facilities will now be supplemented by
- a world-scale
polycarbonate production unit with a starting capacity of 100,000 tons per year,
- the first polyurethane facility at the Bayer site -
a crude MDI (diphenylmethane diisocyanate) splitter with a capacity of 80,000 tons per year and
- a production unit for
HDI (hexamethylene diisocyanate) with an initial capacity of 30,000 tons per year.

The polycarbonate facility for the manufacture of Bayer
s high-tech material Makrolon(R) represents a capital investment of US$ 450 million. There are already plans to expand the capacity of this facility, which will primarily supply customers in the region, to 200,000 tons per year by 2008. Makrolon(R) is used in the manufacture of CDs, DVDs, automotive glazing and many other applications. It is also used in the construction industry: for example, the futuristic roof of the Tianjin Olympic Center Stadium will be made of Makrolon polycarbonate. The company is confident that the material will be used at other sports arenas as well.

The Asia-Pacific region is the biggest market for polycarbonate in terms of volume,
with 1.5 million tons sold last year, more than half the world market of 2.7 million tons. Of this volume, Greater China alone accounts for 650,000 tons, with consumption growing at around 18 percent a year.

Polyurethane raw materials are a further focus of production at the site. These MDI-based intermediates are used in the production of rigid foam for thermal insulation, among other applications. The inaugurated facility - a
splitterthat separates crude MDI into monomeric and polymeric MDI - is just the beginning. A large-scale MDI production facility with a capacity of 350,000 tons per year, due on stream in 2008, will be the largest of its kind in the world. Also planned is a production facility for the intermediate TDI (toluene diisocyanate), which is used to manufacture flexible foams for applications such as car seats, mattresses and furniture. With a capacity of 160,000 tons per year, this plant is expected to come on stream in 2009.

Bayer began its production activities at the site in 2003 with coating raw materials, for which capacity currently is 22,500 tons per year. The company will now be able to produce another
30,000 tons of the raw material HDI, with the option of expanding this capacity by a further 20,000 tons. Polyurethane-based coatings today offer the best performance spectrum. They are used, for example, on the Lupu Bridge - Shanghais most famous landmark - or in high-tech automotive coatings to provide long-term protection against weathering.

International news conference
At a news conference attended by journalists from around the world, Wenning had already outlined the corporate context of the investment projects in Shanghai. After explaining the Bayer Group
s overall strategic realignment, Wenning emphasized the leading positions it holds worldwide in the areas of health care, nutrition and high-tech materials. Bayer had global sales of EUR 27.4 billion in 2005.

The strategic strengthening of the health care business through the acquisition of Schering for approximately EUR 17 billion puts Bayer in seventh position among suppliers of specialty pharmaceuticals, Wenning commented. With Bayer CropScience the world market leader in conventional crop protection and Bayer MaterialScience the number one in polyurethanes and the number two in polycarbonates, Bayer has a highly competitive portfolio, he said.
This portfolio enables us to fully capitalize on our value creation potential, particularly in the Asia-Pacific region,the Bayer Chairman explained.

Bayer has annual sales of EUR 4.6 billion in Asia-Pacific
s sales in the Asia-Pacific region climbed by 15.5 percent in 2005, to EUR 4.6 billion, which means the region accounts for 17 percent of the Groups business. The group has 55 subsidiaries and affiliates in the region, some 14,200 employees, and last year served nearly every local market. Headcount has since risen to about 18,000, including 2,900 Schering employees.

Thanks to high growth rates, the Greater China country group ? which includes the People
s Republic of China, Hong Kong and Taiwan ? already generates 28 percent of Bayers sales in the region, putting it in second place behind Japan. The number of employees has jumped from 3,700 to 4,900 over the past year, including about 600 Schering employees. It is planned to create more new jobs.

High growth rates for Bayer in China
s sales in Greater China grew by 24 percent in 2005, to EUR 1.26 billion. According to Wenning, this shows that Bayer is participating in the regions dynamic economic growth. And this positive trend is continuing: our sales here showed a 22 percent year-on-year gain in the first half of 2006, to EUR 714 million.

Bayer MaterialScience contributed by far the largest share of sales in the first six months, with revenues of this subgroup advancing by 18 percent to EUR 524 million. BMS is targeting sales in excess of EUR 1 billion for the year as a whole. The CropScience subgroup raised sales by 33 percent, with Bayer HealthCare sales growing even faster at 39 percent. The increase at HealthCare was driven mainly by the Pharmaceuticals Division. Including the Schering activities, Bayer ranks fifth among international pharmaceutical suppliers in China.

Bayers Solutions for Chinas Needs
Bayer plans to invest US$ 26 million to enlarge HealthCare production facilities in Beijing, Wenning announced. The company is thus making good on the motto Bayers Solutions for Chinas Needs, a regional variation on the global slogan Bayer: Science For A Better Life. As an example of Bayers commitment to China, the Management Board Chairman mentioned the diabetes initiative of Bayer HealthCare. About 40 million Chinese already suffer from diabetes, and this disease will affect an estimated 50 million people there by 2008. In diabetes houses,Bayer offers patients improved access to diagnosis, treatment, monitoring and consulting services. The medicine Glucobay to treat diabetes is the top-selling product on the Chinese pharmaceuticals market, Wenning said.

For 50 years, the Bayer CropScience subgroup has offered innovative, high-quality products and solutions for local agriculture needs in China. As part of the Agricare initiative, the company trains Chinese farmers in the proper use of crop protection products.

Bayer MaterialScience strives to further improve cooperation with Chinese customers in the development of new applications. To this end, BMS is expanding the Polymers Research and Development Center in Shanghai-Pudong, Wenning explained. The aim is to create an innovative
campusfor all BMS products and applications that is unique in the world.

Sustainable development applies to Bayer worldwide
Wenning emphasized the importance of sustainable-development principles. Bayer strives to uphold the highest possible standards in health, safety and environmental compatibility. This applies worldwide and is thus also valid for the facilities at the Shanghai site, Wenning said, with social responsibility being another fundamental aspect of Bayer
s corporate policy.

The Bayer Management Board Chairman thanked the Chinese authorities, particularly the Shanghai city administration, saying their cooperation and support are essential to the project
s successful implementation.

Wenning also had special words of appreciation for Bayer
s employees and partners, whom he thanked for their enduring cooperation, dedication and commitment. He said it was that commitment that enabled the facilities to be inaugurated on schedule.

October 23, 2006  Bayer

Bayer MaterialScience to acquire Taiwan
s Ure-Tech 台湾優得Group
New global leader in thermoplastic polyurethane resins and films

Bayer MaterialScience will acquire Taiwan
s Ure-Tech Group, the largest thermoplastic polyurethane (TPU) producer in the Asia Pacific region. With this acquisition the Germany-based company will become the worldwide largest supplier and solutions provider of TPU resins and films. The deal is subject to regulatory approval by the cartel office and is expected to be closed in the first quarter of 2007. Both parties have agreed not to disclose purchase price and other related details of the acquisition. In 2005, approximately 180 employees of the Ure-Tech Group generated sales of around USD 55 million. Sales of Bayer MaterialSciences Business Unit Thermoplastic Polyurethanes amounted to 192 million Euros last year with roughly 450 employees.

Combining its activities with Ure-Tech will substantially strengthen Bayer MaterialScience
s existing TPU market position in Asia Pacific, significantly widening and solidifying its market access, especially in Taiwan, China and the South Asian countries. It will become the market leader in TPU resins supply in the Asia Pacific region.

The acquisition will solidly position Bayer MaterialScience to tap into the significant growth potential for TPU resins in the Asia Pacific region, especially China. It also provides the impetus for Bayer MaterialScience to accelerate its global growth in the TPU resins market. In 2005, the total TPU resins and films market was worth about 1.2 billion Euros.

Dr. Hagen Noerenberg, Bayer MaterialScience
s Chairman of the Board, said: We are combining Bayer MaterialSciences global expertise, our international network of customers and locations and our innovative strength with Ure-Techs market access. The company is the leading Asian supplier of TPU resins and has strong local expertise as well as close customer relationships.

As TPU supplier and solution provider of resins and films, we aim to be the number one partner for customers worldwide,said Dr. Tim Bielfeldt, Global Head of Bayer MaterialScience TPU Business Unit.

s CEO, Frank Huang, said: This is a match made out of understanding of both our strengths and special know-how. We complement each other in the areas of production, marketing, research and development.

Together with Ure-Techs production facilities, Bayer MaterialScience will have in close proximity to its customers a total of six TPU resins and two films production facilities in North America, Europe, and the Asia Pacific region. Four of these are in Asia Pacific, in Taichung, Taiwan; Shenzhen in Southern China; Cuddalore, India; and Osaka, Japan (a joint venture with Dainippon Ink & Chemicals, Inc.). The other four are in New Martinsville, West Virginia, USA; South Deerfield, Massachusetts, USA; and in Dormagen and Bomlitz in Germany. The acquisition of Ure-Techs TPU operations will have no negative impact on employees.

About Bayer MaterialScience:
With sales of EUR 10.7 billion in 2005, Bayer MaterialScience AG is one of the world
s largest polymer manufacturers. Its main fields of activity are the production of high-tech polymer materials and the development of innovative solutions for products used in many areas of everyday life. The main consumer sectors are the automotive, electrical/electronics, construction, sports and leisure industries. Bayer MaterialScience has production facilities at 40 sites around the world and a workforce of approx. 18,800. Bayer MaterialScience is part of the Bayer Group.

About Ure-Tech:
Taiwan-based Ure-Tech group is the biggest producer of Thermoplastic Polyurethane (TPU) elastomer in Asia Pacific, manufacturing products under the Utechllan(R) brand. It was founded in May 1992 and now has a manufacturing plant in Taichung, Taiwan, and another production facility in Shenzhen, China. Its UtechllanR brand of TPU is widely used by the footwear and sports and leisure industries among others in the Asia Pacific region.

TAIWAN URE-TECH CO.,LTD. was found in May 1992. Head office is located in Chang Hwa Coast Industrial Park in Chang Hwa, Taiwan. We are a professional manufacturer of Thermoplastic Polyurethane (TPU) elastomer. The
commercial name of products is "Utechllan(R)". Office in Shenzhen, China was established in Oct. 1998. In order to serve the local customers, we have established XUDE RUBBER (SHENZHEN) CO.,LTD. and manufactured products since Sep.2002.


November 23, 2006 Bayer

Auction process successfully concluded:Bayer sells H.C. Starck to Advent International and The Carlyle Group for EUR 1.2 billion

Proceeds will help to finance the Schering acquisition /
Acquirers plan expansion of H.C. Starck business /
Goal is to position the company for an initial public offering in 3 to 5 years

The Bayer Group plans to sell its subsidiary H.C. Starck to a consortium formed by financial investors
Advent International and The Carlyle Group for approximately EUR 1.2 billion. As planned, the proceeds will help to finance the acquisition of Schering. Commenting on the transaction, Bayer Management Board Chairman Werner Wenning said: We are convinced that H.C. Starck will have very good development prospects under the new owners.

The transaction value comprises a cash component of more than EUR 700 million and the assumption of financial liabilities and personnel-related commitments totaling some EUR 450 million. The divestment thus reduces Bayers net debt by about EUR 1 billion, with an accounting gain of about EUR 150 million. Closing is planned to take place at the beginning of 2007, subject to the approval of the antitrust authorities.

Advent and Carlyle intend to continue developing the H.C. Starck business, with the aim of positioning the company for an initial public offering in three to five years. Gregor Bohm, Carlyle Managing Director in Munich, said:
Were delighted to be investing in such a first-class company. H.C. Starck is an extremely innovative and highly specialized enterprise with excellent positions in its various markets. We look forward to working with the entire team to help grow H.C. Starck for the benefit of the company and its employees.

Ralf Huep, General Manager at Advent International in Frankfurt, commented: H.C. Starck is a highly attractive investment. It not only holds leadership positions in its markets, but also has enormous growth potential, both in existing and prospective new business areas. We will work closely with management and Carlyle to leverage these strengths and continue the successful development of H.C. Starcks business.

Bayer conducted the sale of H.C. Starck as an auction process. Several of the many prospective acquirers were invited to examine the company in detail and submit a binding offer. Both strategic and financial investors participated in the bidding through the final stage.

H.C. Starck, headquartered in Goslar in northern Germany, manufactures
metal and ceramic powders, specialty chemicals, and parts made from advanced ceramics and refractory metals. The company employs some 3,400 people and last year posted sales of EUR 920 million. H.C. Starck has 15 sites in Europe, Asia and North America.

Advent and Carlyle are ideal partners for our future expansion,explained H.C. Starck Managing Director Dr. Heinz Heumuller. With their support we will continue to pursue our corporate strategy and business objectives and work to further improve performance.

Bayer announced in March 2006 that it would divest its subsidiaries H.C. Starck and Wolff Walsrode and use the proceeds to partly finance the Schering acquisition. The two companies have so far been part of the Bayer MaterialScience subgroup, which will focus in future on its core businesses.

About Advent International:
Advent International is one of the world
s leading private equity firms, with over EUR 8 billion (US$ 10 billion) in cumulative capital raised and offices in 14 countries across Western and Central Europe, North America, Latin America and Asia. Since its inception in 1984, Advent has invested in more than 500 companies in 35 countries and has taken over 130 of these businesses public on major stock exchanges worldwide. Advent has a proven track record of success in the German market, having concluded eight transactions in the past two years. In 2004, for example, Advent and Carlyle jointly acquired HT Troplast, the worlds leading manufacturer of vinyl profiles for windows and doors.
Vinnolit GmbH & Co. KG)

About The Carlyle Group:
The Carlyle Group is a global private equity firm with more than US$ 46 billion (EUR 36 billion) under management. Carlyle invests in buyouts, venture and growth capital, real estate and leveraged finance in North America, Europe and Asia. Focus industries are aerospace, automotive & transportation, consumer & retail, chemicals, energy & power, healthcare, industrial, technology & business services, and telecom & media. Since 1987, Carlyle has invested total equity capital of US$24 billion (EUR 19 billion) in 576 transactions.

H.C. Starck is an international group of companies with more than 3,400 employees at 14 production sites in Europe, North America and the Far East. 非鉄金属及び希少金属・化合物・セラミックス粉末等の分野で世界に名高いメーカーであるドイツ・スタルク社

H.C. Starck produces an assortment of refractory metal powders that is unique the world over, including tungsten, molybdenum, tantalum, niobium, rhenium as well as their compounds (borides, carbides, nitrides, oxides, silicides, sulfides). A further production focus centers on thermal spray and advanced ceramic powders, nonferrous metals, such as nickel and nickel salts, as well as boron and boron compounds.

In addition to metal powders, semi-finished and finished molybdenum, tungsten, tantalum, niobium, titanium, zirconium and nickel products and their alloys are manufactured. Further to the production of standard components, H.C. Starck is your partner for the manufacture of components according to customers' specifications. Our experts provide answers and solutions to your challenges and problems in all areas ranging from construction to alloying, especially for customized components. As a further service H.C. Starck offers the extrusion of molybdenum and TZM.

H.C. Starck is also a leading supplier of specialty chemicals and products formulated for the electronics industry.

In the engineering ceramics sector H.C. Starck has a wide assortment of ceramic intermediates. Its subsidiary H.C. Starck Ceramics GmbH & Co. KG manufactures machine and engine components, anti-friction bearing components and foundry products made of silicon carbide, silicon nitride, aluminum titanate as well as zirconium and aluminum oxide according to customers' specifications. The H.C. Starck Ceramics R&D laboratory also conducts material tests and process developments for customers.

H.C. Starck became a member of the Bayer Group in 1986 and maintains certified Quality Management Systems at all of its sites. Many locations also have Environment Management Systems.

With its almost 200-year history, the Wolff Walsrode AG is one of Bayer's most traditional production sites. As a holding company, Wolff Walsrode operates the Competence Center for cellulose chemistry and markets the Walsrode Industrial Park (which is now open to outside companies), one of the most highly regarded economic locations in Lower Saxony.

The company has transferred its operations to the independent companies Wolff Cellulosics and CaseTech and the technical service provider Probis. It is particularly strong in the field of cellulose derivatives and services such as engineering, utilities, technical service, logistics, waste management and environmental protection, supporting Bayer Material Science in many key entrepreneurial functions. In this capacity, it makes a vital contribution to enabling its parent company to successfully assert itself as an innovative manufacturer. The CEO of Wolff Walsrode, Dr. Dieter Herzog, has no doubts whatsoever: "We play an important role within the Bayer MaterialScience group and are the driver for technological progress in the field of cellulose chemistry."

Our everyday life would be inconceivable without cellulose derivatives, which are used in a vast number of different products. They serve as thickeners in building materials such as tile adhesives, plasters and emulsion paints and also in foodstuffs, cosmetics and pharmaceuticals, and as binders in printing inks and surface coatings.

With its 1,270 employees, the Wolff Walsrode company posted sales last year of around EUR 329 million.

Bayer 2006/12/7

Bayer MaterialScience Expands Production Network in Asia
s biggest global polycarbonate supplier provides fast local service / Additional EUR 80 million invested in China and India

As demand for Makrolon(R) continues to rise, Bayer MaterialScience AG is steadily increasing polycarbonate production around the world. And at the end of 2006, the company will be producing
1,200,000 tons of Makrolon a year. Additional international spending of around EUR 80 million is to be invested to build up a network in Asia in the next few years, allowing the company to offer excellent technical service locally and supply customers quickly and flexibly. The investments will be used, for example, to build additional compounding plants in China and India. Furthermore, a Color Competence Center (CCC) is to be built at the compounding plant in Shanghai, which has been in production since 2005. Combined with the Polymer Research and Development Center in Pudong, Shanghai, the region will become an important center for Asian and Chinese customers.

Baytown (United States)  260 kt
Antwerp (Belgium)  240 kt
Uerdingen (Germany)  330 kt
Map Ta Phut (Thailand)  270 kt
Shanghai  100 kt
total 1,200 kt

A compounding plant with an integrated Color Competence Center is to come into operation in southern China in the first half of 2008. The next step, planned for the end of 2008, is to use the same concept to invest in Bayer MaterialSciences new site in New Delhi (India). In this way, several locations in Asia will be added to the successful network of existing compounding plants with integrated Color Competence Centers in Filago (Italy), Newark (Ohio, United States) and Map Ta Phut (Thailand).

Thanks to these investments in China, southern China and India, Dr. Gunter Hilken, head of the Polycarbonates Business Unit at Bayer MaterialScience, is convinced that his sector is well equipped to deal with whatever the future holds:
As a solution provider we do everything in our power to provide users of plastics with optimum support during both development and production. This means we have to be close to our customers in terms of geographical location, too. We want them to benefit from our technology network and from the security and stability of a global corporation, without having to forgo fast, local service. At the same time, we offer a complete range of polycarbonate products and are the driving force behind innovation in our industry sector.

To keep pace with market demand for Makrolon, Bayer MaterialScience increased the capacity at its existing large-scale plants by a total of 170,000 tons between 2004 and 2005. The annual capacity is split among sites in Baytown (United States) providing 260 kt, Antwerp (Belgium) 240 kt, Uerdingen (Germany) 330 kt, and Map Ta Phut (Thailand) 270 kt. Commissioning the new plants at the Shanghai integrated production site in 2006 achieved an additional annual capacity of 100 kt for the fast-growing market in Asia. Due to the continued increase in demand, this additional capacity is to be doubled during 2008. When capacities for Makrolon production are added together, Bayer MaterialScience produces 1.2 million tons of Makrolon a year, making it the biggest manufacturer of polycarbonates in the world.

Thanks to its exceptional characteristics, Makrolon is the material of choice for many high-tech applications in the electrical engineering and electronics industry, the construction sector, the automotive industry and in the field of packaging and medical products. It is practically unbreakable, lightweight, impact resistant even at low temperatures, as transparent as glass and displays a high level of heat resistance. Polycarbonate is mixed with other plastics to produce a diverse range of applications and is offered as blends. Polycarbonate films and sheets are also becoming increasingly important.

With sales of EUR 10.7 billion in 2005, Bayer MaterialScience AG is one of the world
s largest polymer manufacturers. Its main fields of activity are the production of high-tech polymer materials and the development of innovative solutions for products used in many areas of everyday life. The main consumer sectors are the automotive, electrical/electronics, construction, sports and leisure industries. Bayer MaterialScience has production facilities at 40 sites around the world and a workforce of approx. 18,800. Bayer MaterialScience is part of the Bayer Group.

Bayer December 12, 2006

Bayer MaterialScience expands MDI production capacity in Tarragona to 150,000 tons a year
Location is key component of global production network

Bayer MaterialScience AG has now completed the expansion of its production facilities for
methylene diphenyl diisocyanate (MDI) in Tarragona, Spain by 50,000 tons a year to an annual capacity of 150,000 tons. As a result, the company has a global production capacity of almost 1.1 million tons per year. Plant capacity at Tarragona for the intermediates carbon monoxide (CO) and methylene diphenyl diamine (MDA) has also been expanded.

This expansion is our response to the growing demand for MDI in Eastern and Western Europe and the Middle East,says Peter Vanacker, head of the Polyurethanes Business Unit at Bayer MaterialScience. We are thereby underlining our leading position in the polyurethane industry and are now in a position to provide even better service and support for our customers as they continue to grow. Furthermore, as a key location in our global production network, Tarragona will continue to supply customers in other regions as well.

MDI production facilities in Krefeld-Uerdingen (Germany) were also expanded in summer 2006 by 36,000 tons to a capacity of 200,000 tons a year. At its integrated Shanghai site, Bayer MaterialScience is currently building world-scale production facilities capable of producing 350,000 tons of MDI each year. The facilities are to start operating in 2008 and will mainly supply customers in the Asia-Pacific region. A splitter used to extract monomeric and polymeric MDI from crude MDI that has a plant capacity of 80,000 tons a year went into operation there in June 2006. Bayer MaterialScience also operates production facilities for MDI in Brunsbuttel (Germany), Baytown and New Martinsville (both United States), Belford Roxo (Brazil) and Niihama (Japan).

With sales of EUR 10.7 billion in 2005, Bayer MaterialScience AG is one of the world
s largest polymer manufacturers. Its main fields of activity are the production of high-tech polymer materials and the development of innovative solutions for products used in many areas of everyday life. The main consumer sectors are the automotive, electrical/electronics, construction, sports and leisure industries. Bayer MaterialScience has production facilities at 40 sites around the world and a workforce of approx. 18,800. Bayer MaterialScience is part of the Bayer Group.

October 11, 2006
Bayer MaterialScience closes MDI Facility at New Martinsville, W.Va., USA
The methylene diphenyl isocyanate (MDI) facility at the Bayer MaterialScience plant in New Martinsville, W.Va., with an annual design capacity of 160 million pounds (approx. 73kt), will close on June 30, 2007. Approximately 230 positions will be affected by the closure.
The economies of scale are changing in the MDI marketplace, and Bayer is consolidating production to several world-scale plants, including its plant in Baytown, Texas,said Jim Covington, New Martinsville General Plant Manager.
To better serve our Northeastern U.S. customers, New Martinsville will continue to be an MDI, TDI and HCL transloading and distribution center, sourcing material from our Baytown plant.
The New Martinsville facility will continue to produce other isocyanates and polyols, coatings raw materials and thermoplastic polyurethanes, Covington said. Isocyanates and polyols are combined to make flexible and rigid polyurethane foams, which are used in furniture, automotive, construction, appliance and sporting goods applications.
Changing technology capabilities and market requirements have lead to new standards for world-scale facilities. Therefore Bayer's MDI production has been consolidated into expanded facilities in Baytown, and further world-scale plants in Uerdingen and Brunsbuettel, Germany; and Tarragona, Spain. Bayer is currently constructing the world's largest single-train MDI facility with a capacity of 350 kt pa in Caojing, China, which is setting a new standard in the industry. This plant is expected to come on stream in 2008.
By concentrating our capacities in these high-technology, high-performance facilities, we are ideally equipped for the future and will be able to react to increased global demand for MDI with cost-effective production,said Michael Koenig, Senior Vice President of Global Production and Technology, Isocyanates. With the investment in Caojing, we demonstrate the implementation of our strategy to follow our customers and produce MDI locally.
Bayer MaterialScience LLC is one of the leading producers of polymers and high performance plastics in North America and is part of the global Bayer MaterialScience business with nearly 19,000 employees at 40 sites around the world and 2005 sales of 10.7 billion euros. Our innovative developments in coating, adhesive and sealant raw materials, polycarbonates, polyurethanes and thermoplastic urethane elastomers enhance the design and functionality of products in a wide variety of markets, including the automotive, construction, electrical and electronics, household and medical industries, and the sports and leisure fields. Our inorganic basic chemicals unit produces chlorine and related essential products for the chemicals industry.

February 7, 2007 Bayer

First facility of its kind in China:
Bayer establishes APAC spray competency center in Shanghai
Strong growth for composite materials in China

Bayer MaterialScience has set up a spray competency center in Shanghai, China, to demonstrate its expertise in polyurethane spray technology in the Asia Pacific region. It features state-of-the-art processes and technologies for reinforced and un-reinforced systems. The spray competency center, located within Bayer MaterialScience
s Polymer Research & Development Center (PRDC) in Shanghai, is one of three regional facilities established globally by Bayer MaterialScience.

The center reflects Bayers leadership in the field of polyurethanes spray competency,said Dr. Thomas Braig, Asia Pacific Marketing Director for BaySystems Molded Parts & Elastomers of Bayer MaterialScience. At our spray competency center, we bring together both high-tech spray machines, as well as our advanced polyurethane spray systems. Our aim is to optimally support our customers in the development of applications based on our full range of polyurethane spray systems.

In addition to the BaytecR Reactive polyurethane system, a thick, high quality film coating used to waterproof buildings and to protect bridges, truck beds and other large structured parts against corrosion, the spray center also features Bayer MaterialSciences MultitecR and BaypregR polyurethane spray technologies.

Both technologies stand for highly versatile polyurethane spray systems that enable the efficient production of high-performance, light-weight composite structures based on polyurethanes,said Roy Lin, Head of Business Development for BaySystems Molded Parts & Elastomers, and Automotive Systems. They allow for efficient wet-in-wet manufacturing with easy handling, without any need for post-curing. Additionally, our spray system is solvent- and styrene monomer-free. This environmental friendly technology is beneficial for all customers, in particular for export business to Europe and the US,he noted.

Examples of MultitecR application areas are bathtubs, tractor fenders and other molded parts which require a high quality surface top layer with reinforced structure. The BaypregR spray system is processed in a mold that can be combined with a wide range of reinforced cores, such as glass, carbon fiber, polystyrene, or honey comb, enabling a high-performance and light-weight composite solution. There are various application examples of the spray system in the automotive and truck industry, as well as in surf and ski boards and even furniture parts.

Braig noted how such applications have contributed to the growth in demand for composite materials.
Demand for composite materials has grown rapidly in recent years, and has exceeded 10 percent annual growth rates in markets such as China,Braig said. Our polyurethane systems MultitecR and BaypregR offer significant advantages in terms of quality, productivity and efficiency, as well as environmental-friendliness, compared to conventional fiber reinforced plastics based on unsaturated polyester or epoxy resins. Our polyurethane spray systems are the right solution for all customers who want to be competitively prepared for the future. With the spray center, we are prepared to support them.

With 2005 sales of 10.7 billion euros, Bayer MaterialScience AG is among the worlds largest polymer companies. Business activities are focused on the manufacture of high-tech polymer materials and the development of innovative solutions for products used in many areas of daily life. The main segments served are the automotive, electrical and electronics, construction and the sports and leisure industries. At the end of 2005, Bayer MaterialScience employed approximately 18,800 people at 40 production sites around the globe. Bayer MaterialScience is a Bayer Group company.

2009/1/26 Bayer

Bayer builds world's largest production plant for carbon nanotubes in Chempark Leverkusen

Bayer MaterialScience has begun work on the construction of a new facility for the production of carbon nanotubes (CNTs) in Chempark Leverkusen. The new plant will have a capacity of 200 tons/year, making it the largest of its kind in the world. The company is to invest around EUR 22 million in the planning, development and construction of the plant, which will create 20 new jobs. "We are investing in a key technology of the future that will open up a broad range of new applications for us. We intend to utilize this opportunity to the full. At the same time, the construction of the new CNT facility is a declaration of faith in Leverkusen and the State of North Rhine-Westphalia as an industrial location," said Dr. Wolfgang Plischke, the member of the Bayer AG Board of Management responsible for innovation, technology and the environment, at a press conference to mark the start of construction. Current forecasts predict that the global market for carbon nanotubes will grow by 25 percent a year. In ten years, annual sales of these products are expected to reach US-Dollar 2 billion.

Following the official start of construction work, representatives of the Innovationsallianz "CNT - carbon nanomaterials conquer markets" - in brief: Inno.CNT - met in Chempark Leverkusen for their kick-off event. In this alliance, which is supported by the German Federal Ministry for Education and Research (BMBF), more than 70 partners from industry and science have joined together to develop new technologies and applications for CNT-based materials.

Bayer MaterialScience is one of the few companies that can produce carbon nanotubes of consistently high quality on an industrial scale. A pilot plant with an annual capacity of 60 tons has been in operation in Laufenburg in southern Germany since 2007. Production involves a catalytic process in which the carbon nanotubes are obtained from a carbon-containing gas at elevated temperature in a reactor. "Bayer is investing in this, the world's largest CNT production plant, because we are convinced of the technological and economic efficiency of the process," said Plischke.
With the company's know-how, Bayer can now take a product from the research laboratory and smooth its progress into a broad spectrum of applications relevant to society, such as energy, the environment, mobility, safety and construction. Baytubes
® ? the brand name for Bayer's carbon nanotubes ? are already being used to produce tough, extremely strong, lightweight materials. This means, for example, that rotor blades for wind turbines are more energy-efficient, that transport containers weigh less and that sports equipment can be made more robust.

Innovationsallianz CNT to enhance competitiveness
Plischke also welcomed Thomas Rachel, Parliamentary State Secretary in the BMBF ? the ministry backing the project ? to the event. Future developments in the field of CNT-based materials are to focus on applications involving energy and the environment, mobility and lightweight construction. A total of EUR 80 million will be invested in research and development as part of Inno.CT, of which the BMBF will contribute about EUR 40 million. In addition, the participating companies want to invest up to EUR 200 million in the further development of these technologies and applications during the course of the projects and also after their conclusion.

Rachel pointed out that Germany and the European Union had set themselves ambitious climate targets. To achieve them, he said, efficient and responsible energy management was essential. The German government wanted to significantly reduce energy consumption in Germany by 2020, and new materials would make a major contribution to this.

Rachel: "Carbon nanotubes will play a particularly important role. They offer all kinds of benefits, such as improving fuel and battery technologies and reducing the weight of vehicles. To exploit the enormous potential of these new materials, the German Federal Ministry for Education and Research will fund the Innovationsallianz CNT to the tune of around EUR 40 million over a period of four years. This alliance will play a significant part in implementing the Federal government's high-tech strategy, through which we aim to strengthen Germany's competitiveness."

The main purpose of the two-day kick-off event in Leverkusen for the alliance partners was to exchange technical ideas and coordinate further cooperation on the project.